FEHBlog

Weekend Update

Simplicity is a virtue.

From Washington, DC,

  • Congress will be out of session this week following the semiquincential holiday.
  • STAT News reports,
    • “Dozens of congressional lawmakers are urging the Trump administration to force Eli Lilly to reinstate mandated price breaks to hospitals that participate in a federal drug discount program but have refused to provide the company with claims data.
    • “In a letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr., the bipartisan group of lawmakers argued that Lilly is failing to comply with federal law by eliminating the price breaks. The drugmaker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals.” * * *
    • “Congress did not authorize manufacturers to unilaterally impose additional reporting mandates or data-sharing requirements as a prerequisite for obtaining those discounts,” the lawmakers wrote. “Lilly’s actions effectively condition participation in the 340B program on compliance with manufacturer-imposed requirements that extend beyond the statutory framework established by Congress.”
  • On July 3, a federal holiday, the Office of Management and Budget’s Office of Information and Regulatory Affairs posted the “2026 Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions,” which was historically known as the semi-annual regulatory agenda.
  • The Office of Personnel Management’s agenda includes the following FEHB / PSHB related rules:
    • “This proposed rule [RIN: 3206-AO45, projected to be published in September 2026] would implement section 9816 of the Internal Revenue Code of 1986, section 716 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 2799A1 of the Public Health Service Act (PHS), as directed by section 111 of the No Surprises Act; and may include other provisions under the Consolidated Appropriations Act, 2021. Pursuant to 5 U.S.C. 8902(p), Federal Employees Health Benefits (FEHB) carriers must comply with Advanced Explanation of Benefits requirements in the same manner as those provisions apply to a group health plan or health insurance issuer offering group or individual health insurance coverage. This rule would also clarify that FEHB carriers must comply with the applicable Medicare limits set forth at 5 U.S.C. 8904(b) notwithstanding a payment determination calling for a payment in excess of those limits.”
    • “OPM is proposing new standards [RI: 3206-AO93, projected to be published in November 2026] to improve enrollment integrity and accuracy in Federal employee benefits programs, including the Federal Employees Health Benefits (FEHB) and Federal Employee Group Life Insurance Programs. This would include amendments to 5 CFR parts 870 and 890 to establish a new eligibility determination process for children who are age 26 and over and who are incapable of self-support (ISS). In addition, OPM will (1) allow employing offices to adjust enrollment type from Self and Family or Self plus one to Self Only if there is only one person covered by the enrollment and (2) prohibit ineligible family members from receiving a 31-day extension of coverage when their coverage is terminated due to a reduction in the enrollee’s enrollment type.”
    • This proposed rule RIN: 3206-AP13; projected to be published in July 2027) would implement section 108 of the No Surprises Act.” Section 108 requires the No Surprises Act regulators to promulgate a rule describing the requirements of Public Health Service Act Section 2706, which is the Affordable Care Act’s provider non-discrimination provision.
    • The Office of Personnel Management (OPM) is amending its regulations to implement the Administrative False Claims Act of 1986, as amended by the National Defense Authorization Act for Fiscal Year 2025 [RIN: 3206-AP00; projected to be published this month]. This proposed rule would revise the administrative procedures for imposing civil penalties and assessments against persons who make, submit, or present false claims and statements to OPM.
  • OPM’s announced in LinkedIn
    • “Fraud in federal healthcare programs isn’t a rounding error — it’s likely billions of dollars a year, and it’s now a White House priority.
    • “I’m hiring the engineering leader who’ll help make that fight real from the inside. U.S. Office of Personnel Management (OPM) is looking for a Division Chief to lead our Healthcare Engineering Division — working directly with the White House Task Force to Eliminate Fraud, chaired by Vice President Vance. This role owns the technical work behind better services and lower costs and leads the AI/ML systems, infrastructure, and full SDLC for programs touching millions of federal employees, retirees, and their families.
    • “GS-15 scope: $147,945–$197,200, budget authority over major IT investments, a team of engineers and data scientists reporting to you.
    • “If you want engineering work with real consequences, apply by July 8.”
  • FEHBlog observation – Since the late 1980s, OPM’s Inspector General has been fighting fraud, waste, and abuse “from the inside” with strong, effective support from the FEHB and PSHB carriers which hold the financial risk for their plans.
  • ACDIS tells us,
    • “CMS has published the fiscal year (FY) 2027 ICD-10-CM code set, including 190 new codes, 30 deleted codes, and four revised codes. These updates will become effective on October 1, 2026.
    • “Of the 190 new codes, 33 are related to continuing pregnancy after vanishing twin syndrome (category O31.4) and 17 codes related to the toxic effect of cycloparaffins (category T52.82).”

From the public health and medical / Rx research front,

  • The Wall Street Journal explains new developments in sunscreens sold in our country.
  • Healio reports,
    • “Adults with type 2 diabetes who were provided medically tailored healthy meals and lifestyle counseling for 6 months had a lower HbA1c than those who received a monthly food subsidy, researchers reported.
    • Food insecurity is a common barrier to eating healthy meals for people with diabetes, according to Seth A. Berkowitz, MD, MPH, associate professor of medicine at University of North Carolina School of Medicine. In an open-label, parallel-group, randomized trial presented at the American Diabetes Association Scientific Sessions, Berkowitz and colleagues compared health outcomes among two nutritional interventions: medically tailored meals that were created and delivered directly to people’s homes, and subsidies where participants received money to purchase food themselves.”
  • and
    • “A single injection of sura-vec reduced the severity of nonproliferative diabetic retinopathy for up to 2 years, according to data presented at Optometry’s Meeting.
    • “Early intervention is essential to prevent progression to blinding complications, yet the burden of frequent intravitreal injections with current anti-VEGF therapies make long-term treatment difficult for many patients,” Steve Pakola, MD, chief medical officer at Regenxbio, told Healio. “We believe sura-vec has the potential to redefine the treatment paradigm by delivering sustained anti-VEGF expression through a one-time, in-office gene therapy, reducing treatment burden while helping preserve vision long-term.”
  • Health Day informs us,
    • “More than half the calories consumed by young kids in the U.S. come from ultra-processed foods.
    • “Now, a new study warns that those foods, including sugary cereals, packaged snacks, fast food and processed meats, may be linked to measurable differences in brain structure by age 6.
    • “A team at Children’s Hospital Los Angeles followed 144 Latino and Hispanic mother-child pairs from infancy through age 6, tracking kids’ diets over time and using MRI scans to measure brain structure.” * * *
    • “Our findings suggest that what children eat early in life may shape brain development in ways we’re just beginning to understand,” said senior author Michael Goran, director of the Nutrition and Obesity Program at the hospital’s Saban Research Institute. “Even without differences in cognitive performance, we’re seeing measurable changes in brain structure.”
    • “More work is needed to understand what these structural differences may mean for long-term health.”
  • and
    • “Here’s more pressure for harried mothers — a sluggish response to baby’s coos and babbles might increase their risk of childhood psychiatric problems.
    • “Moms who respond within one second of their baby’s vocalizations appear to lower the child’s risk of mental health problems by age 7, researchers reported July 1 in the journal PLOS One.
    • “Specifically, for every 10% increase in the likelihood of a mom responding within a second, the child’s odds of a later psychiatric diagnosis decreased by 17%, researchers found.
    • “The results “suggest a robust association between slow parental responses to their infants’ signals and later problems,” senior researcher Philip Wilson, an emeritus professor at the University of Aberdeen in the U.K., said in a news release.”

From the U.S. healthcare business and artificial intelligence front,

  • HealthExec reports,
    • “More than half of all patients taking GLP-1s such as semaglutide are using them to treat a diagnosed medical condition, signaling that the demand for the popular weight loss drugs may not be purely for vanity, a new study using payer claims data reveals.
    • “In its report, healthcare market research firm Trilliant Health was able to show that, while popular GLP-1 substances such as Ozempic, Zepbound and Wegovy may have been originally approved to manage blood sugar, their medical use has expanded significantly since the latter was given FDA approval for chronic weight management in 2021, spurring the modern trend.
    • “According to the data analyzed by Trilliant, the number of patients prescribed this class of pharmaceuticals has risen nearly 636% between 2018 and 2024, when the data cuts off. Notably, the first GLP-1 approved to be prescribed for weight management was Saxenda, given the greenlight in 2014 for adults.” * * *
    • “The most common indication for why patients were prescribed GLP-1s was obstructive sleep apnea, potentially directly related to obesity, coming in at 25.5% of scripts. The second highest medical condition was major depressive disorder, coming in at 18.2%.
    • “After that, chronic kidney disease was the most common reason for prescriptions at 10.6%, followed by fatty liver disease.
    • “Trilliant noted that conditions related to overeating specifically—binge eating—were the least common reason for patients to be given the drugs, coming in at only 0.5%.
    • “The firm added that, when considering that many patients were also prescribed GLP-1s for more than one medically valid condition, demand for the drugs will only grow, and payer plans should be prepared for the continued spike.” * * *
    • “The full report is available by clicking here.”
  • Medscape adds,
    • “Substance use disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, and early clinical data suggest these drugs may reduce the cravings that drive addiction.
    • “Interest has accelerated over the past few years, fueled by reports that patients taking semaglutide or tirzepatide for diabetes or obesity drink less alcohol, smoke fewer cigarettes, or experience fewer cravings. Those observations have prompted a wave of studies exploring whether these drugs could have a role in treating alcohol, nicotine, opioid, and other SUDs.
    • “More recently, large retrospective analyses have suggested that GLP-1s may be associated with lower rates of overdose, SUD-related mortality, and new-onset SUDs.
    • “At this point, however, much of the evidence comes from animal studies, observational research, and patient reports. Definitive answers will require randomized clinical trials. More than 30 studies are now investigating GLP-1s for alcohol, nicotine, opioid, cocaine, and methamphetamine use disorders, making addiction one of the fastest-growing areas of GLP-1 research.”
  • BioPharma Dive relates,
    • Celea Therapeutics, a biotechnology startup testing a next-generation treatment for idiopathic pulmonary fibrosis, said in a Thursday announcement it has brought in $180 million to continue its work.
    • Launched in 2025, the PureTech Health spinout is working on a medicine that it says is a retooled version of pirfenidone, also known as Roche’s Esbriet, a drug that slows the progression of scarring in the lungs.
    • The venture round was backed by RA Capital Management, Leaps by Bayer and PureTech, as well as two other unnamed funds. The proceeds from this fundraising will be used to launch its drug deupirfenidone into late-stage testing in the third quarter of 2026.
  • HR Dive tells us,
    • HR is still adapting to artificial intelligence rather than taking the lead on redesigning the workflow around AI, according to a report released by the Institute for Corporate Productivity (i4cp) Tuesday [June 30].
    • After surveying more than 1,300 business and HR leaders worldwide, i4cp researchers determined that even though workplaces are moving past “isolated AI use cases,” AI implementation is still a “series of disconnected experiments,” according to a Tuesday statement.
    • AI is increasing expectations for what HR practitioners are expected to bring to the table, but “most HR functions are still experimenting at the margins rather than redesigning how work actually gets done,” Katheryn Brekken, senior research analyst at i4cp, said in a statement.

Cybersecurity Saturday

From the Project Glasswing front,

  • Cybersecurity Dive reports,
    • “Anthropic on Wednesday [July 1, 2026] unfroze access to its advanced Fable and Mythos AI models after the Trump administration lifted an export-control ban.
    • The return of the two models — with Fable 5 available for general use and the more powerful Mythos 5 limited to a coalition of trusted partners, as it was prior to the ban — represents significant progress in ongoing talks between President Donald Trump’s administration and AI firms over the responsible deployment of frontier AI models, an issue the U.S. government and the tech industry have sparred over in recent months.
    • “In a Tuesday statement announcing a resolution to one of the AI race’s most intense clashes, Anthropic insisted that its models had always been safe and that the government had blown the situation out of proportion — suggesting that tense conversations still lie ahead about the balance between offering advanced capabilities to defenders and keeping them out of the hands of U.S. adversaries.”
  • Bleeping Computer adds,
    • “Anthropic says Claude Fable 5 won’t be accessible via Claude subscriptions after July 7, but it’s not a permanent change, and the company expects the model to return outside the usage-based plan soon.
    • “Fable 5 was recently restored after the US government lifted export controls on Anthropic’s most powerful models, Fable 5 and Mythos 5.
    • “As part of the redeployment, Anthropic said Fable 5 would be available globally on Claude.ai, Claude Code, Claude Cowork, and the Claude Platform.”
  • and
    • “Claude Fable, the company’s most powerful model, is now available to all users, but early impressions are disappointing, as it appears to be nowhere near the original release.” * * *
    • “[T]he real gut punch is the degraded performance, or as famously used in the AI community, the “nerfed” performance.
    • “On Reddit, users are reporting that the restored Fable 5 feels weaker, or is simply being routed through stricter safety systems more often than before.
    • “The new guardrails are kicking in on way too many tasks and falling back to Opus 4.8,” one user wrote in a Reddit post. “This is not the model that got banned.”
    • “The problem is not just limited to Claude desktop, as Claude Code is also struggling with similar issues.”
  • Observer interviews CrowdStrike president Michael Sentonas who “discusses Anthropic’s Claude Mythos and how A.I. could speed up vulnerability discovery and exploitation.”

From the cybersecurity policy and law enforcement front,

  • Cyberscoop reports,
    • “The Department of Homeland Security is bringing back a key cybersecurity information sharing effort with critical infrastructure, more than a year after the Trump administration shuttered an existing nerve center between government and private sector.
    • “The Alliance of National Councils for Homeland Operational Resilience – Critical Infrastructure program, first reported by CyberScoop in January, is meant to replace the function of the Critical Infrastructure Partnership Advisory Council.
    • “CIPAC was a federal advisory body that allowed agencies like the FBI, the Cybersecurity and Infrastructure Security Agency and the intelligence community to interact with key owners and operators of water, power, internet and telecommunications to coordinate on cyberattacks and digital vulnerabilities. ANCHOR will fulfill a similar role.
    • “ANCHOR-CI will provide forums through which cybersecurity, law enforcement, intelligence, national security, and other government representatives at the federal, state, local, tribal, and territorial levels may engage representatives of private sector entities and critical infrastructure owners and operators in reviewing the current threat environment, discussing potential vulnerabilities, and forming recommendations on securing a more resilient critical infrastructure and cyberspace,” DHS wrote in a federal register notice set to publish July 1.
    • “ANCHOR-CI will be managed by CISA, which will appoint members to the council from industry, trade associations, state and local governments and other sources.
    • “The body will consist of four types of different councils: one focused on federally designated critical infrastructure sectors, cross-sector councils to deal with emerging threats like cyber attacks or zero-day vulnerabilities, critical infrastructure industry councils and regional coordinating councils.”
  • and
    • “Trump administration budget chief Russell Vought told lawmakers Tuesday that he’s willing to work with Department of Homeland Security Secretary Markwayne Mullin on re-staffing up the Cybersecurity and Infrastructure Security Agency, following deep personnel cuts and further proposed reductions in the fiscal 2027 budget blueprint.
    • “Mullin said last week at a House Appropriations Subcommittee on Homeland Security hearing that he would like to hire 600 more people at CISA, similar to remarks he made earlier this month at another House hearing. President Donald Trump has cut or lost more than 1,000 from an agency that stood around 3,400-strong at the end of the Biden administration — cuts criticized by lawmakers in both parties.”
  • Federal News Network relates,
    • “The National Institute of Standards and Technology expects to advance high profile standards work around a “Cyber AI Profile” and securing artificial intelligence agents this summer, amid a flurry of federal activity aimed at addressing both the risks and opportunities for AI and cybersecurity.
    • “NIST’s National Cybersecurity Center of Excellence (NCCoE) is now running six distinct projects focused on the intersection of AI and cyber. But Cherilyn Pascoe, director of the NCCoE, said AI is popping up across the center’s work, which focuses on practical guidance to advance secure technologies in collaboration with government agencies, industry and academia.
    • “I think AI is going to be part, if not a leading part, of every project going forward at the center,” Pascoe said in an interview. “It is becoming so foundational to cybersecurity.”
    • “Recent advancements in AI models like Anthropic’s Claude Mythos have shown the ability to quickly find software vulnerabilities and create cyber exploits much faster than humans.”
  • Security Week tells us,
    • “Google, the FBI, and other organizations coordinated in a joint effort to dismantle NetNut, a massive residential proxy network.
    • “Also known as Popa, NetNut is believed to consist of more than 2 million Android devices such as smart TVs and streaming boxes, that have been infected through trojanized applications and malware such as Badbox 2.0.
    • ‘The network’s operator, linked to the publicly-traded Israeli firm Alarum Technologies Ltd, rented the residential proxies to various threat actors, including cybercriminal and espionage groups.
    • “In a single week in June, Google observed 316 distinct threat clusters using NetNut to hide their locations in password-spray attacks and to access victim environments.
    • “We believe our coordinated actions have caused significant degradation to NetNut’s proxy network and its business operations, reducing the available pool of devices for the proxy operator by millions,” Google said.
    • “As part of the operation, the internet giant disabled Google accounts and associated services used for command-and-control (C&C), dismantling the botnet’s backend infrastructure.”
  • Cyberscoop informs us,
    • “19-year-old alleged member of the Scattered Spider extortion crew was extradited to the United States last week and remains in federal custody awaiting several cybercrime charges, the Justice Department said Wednesday. 
    • “Peter Stokes, a dual citizen of the United States and Estonia, was allegedly involved in Scattered Spider since it formed in 2022 and boasted on social media about the luxurious globetrotting life he enjoyed while he was still a child. 
    • “The cybercrime ring of young, native English-speaking people has infiltrated more than 100 businesses since 2022, and extorted more than $100 million from its victims around the world, officials said.” 

From the cybersecurity breaches and vulnerabilities front,

  • HIPAA Journal reports,
    • “Verizon Business has released the findings from its inaugural Breach Impact Study, which focuses on the financial impact of data breaches. The BIS report is from the same authoring team as the Verizon Data Breach Investigations Report and was produced in partnership with CyberAcuView. The report is based on an analysis of around 70,000 U.S. cyber insurance claims, including 38,000 claims where the policies paid out. The data spans from January 2019 to October 2025.
    • “In contrast to many data breach cost reports, the report is based on median claim amounts rather than averages, which are susceptible to skewing. In 2019, the median financial impact was around $60,000, rising by 80% to $110,000 in 2025, with data breach costs outpacing inflation, which was around 23% over the period of the study. More than half of paid-out claims exceeded $83,000, with 10% having an impact of $920,000 or more. The most extreme 2.5% of cases exceeded $5 million in losses.
    • “The report shows that data breach costs almost doubled between 2019 and 2025, with business interruption the single largest loss driver, followed by loss to threat actor and response and recovery.”
  • MedTech Dive relates,
    • “Medtronic has begun to notify people who may have been affected by a cyberattack that was disclosed more than two months ago.
    • “Medtronic provided the update in a statement posted to its website on Monday [June 29, 2026]. At this time, Medtronic has no evidence the data that was accessed has been publicly posted or exposed to the internet, according to the statement.
    • “The company is providing 24 months of complimentary credit monitoring, dark web monitoring and identity theft restoration services. It is also setting up a dedicated call center to address questions for those affected.”
  • Bleeping Computer tells us,
    • “The Department of Homeland Security is investigating a cyberattack that compromised the Homeland Security Information Network (HSIN), a sensitive information-sharing platform used by federal, state, local, and private-sector partners.
    • “The intrusion, first reported by Nextgov, was carried out by an unknown threat actor in recent weeks and is believed to have occurred sometime between late May and early June, according to two people familiar with the matter who spoke on the condition of anonymity.
    • “DHS is currently investigating the attack and has reportedly not attributed it to any specific threat actor or foreign governments. Whether any documents were stolen from the system also remains unclear.”
  • Cyberscoop informs us,
    • “Toolkits to wage phishing campaigns are a now-venerable instrument for cybercriminals, but researchers recently turned up details on something like a full-fledged “business email compromise-as-a-service” platform.
    • “Cisco Talos said Wednesday that it had found an operator panel dubbed ARToken, which shares infrastructure and other things in common with, and as an affiliate to, the EvilTokens phishing-as-a-service operation built to bypass multi-factor authentication and compromise Microsoft 365 accounts. EvilTokens has reportedly seen a dramatic increase in its phishing attacks — by 1,380% early this year compared to the same period last year — with an assist from artificial intelligence integration.
    • “ARToken is notable, though, for the capabilities that go beyond what’s been made public about EvilTokens so far by companies like Sekoia and Microsoft itself, such as inbox rule manipulation and shared access links.
    • “These features indicate the platform is more mature than a simple device code phishing kit — it is a complete BEC operations environment,” wrote Michael Kelley, security research engineer at Cisco Talos, in a blog post, referring to business email compromise scams that involve sending fake emails to solicit fraudulent payments.”
  • and
    • “Citrix published a security bulletin Tuesday [June 30] disclosing six vulnerabilities in NetScaler ADC and NetScaler Gateway appliances, including a high-severity memory disclosure flaw that researchers say belongs to a vulnerability class first identified in the 2023 incident known as CitrixBleed.
    • “The company rated the overall bulletin severity as high and assigned CVSS scores ranging from 6.9 to 8.8 across the six CVEs. Citrix said customers should install the updated builds and, in one case, manually adjust a configuration parameter even after patching.
    • “The most closely scrutinized of the vulnerabilities, CVE-2026-8451, was discovered by researchers at watchTowr, a cybersecurity firm that has published several prior analyses of issues in NetScaler products. According to a technical writeup the firm released alongside Tuesday’s disclosure, the vulnerability stems from how NetScaler parses SAML authentication requests when an appliance is configured as a SAML identity provider, a deployment mode commonly used for single sign-on.”
  • CISA added two known exploited exploits (KVE) to its catalog this week.
  • Bleeping Computer adds,
    • “CISA confirmed on Monday that ransomware gangs have begun exploiting a high-severity Microsoft Defender privilege escalation vulnerability that has previously been abused in zero-day attacks.
    • “Dubbed BlueHammer, the security flaw (CVE-2026-33825) was leaked by a security researcher known as “Nightmare Eclipse” in early April, together with proof-of-concept exploit code, in protest at how the Microsoft Security Response Center (MSRC) handles the disclosure process.
    • “Insufficient granularity of access control in Microsoft Defender allows an authorized attacker to elevate privileges locally,” Microsoft explains in a security advisory.”
  • Dark Reading notes,
    • “NIST has reduced the number of CVEs receiving enrichment in the National Vulnerability Database since April due to a growing backlog, impacting the data available to security teams.
    • “Research from Volerion found that, between April 15 and June 15, only 6,759 out of 13,441 non-rejected CVEs published to the NVD received NIST enrichment, causing coverage gaps, delayed analysis, and reliance on inconsistent CVSS scores provided by over 500 CVE Numbering Authorities (CNAs).
    • “Volerion’s analysis identified issues with timeliness, enrichment quality, and scoring discrepancies—especially in critical metrics such as attack complexity—potentially causing organizations to misjudge vulnerability severity and prioritize incorrectly.
    • “The report urges organizations not to rely solely on NIST or CNA CVSS scores for risk assessment, recommending the use of diverse metrics and independent analysis for more accurate prioritization.”
  • Security Week points out,
    • “Cisco confirmed that a recently patched vulnerability in its Unified Communications Manager (Unified CM) and Unified Communications Manager Session Management Edition (Unified CM SME) has been exploited in the wild.
    • “Tracked as CVE-2026-20230 (CVSS score of 8.6), the security defect is described as the improper validation of specific HTTP requests, which could allow attackers to mount SSRF attacks.
    • “Successful exploitation of the bug could lead to arbitrary files being dropped to the underlying operating system, which could then be used to gain root access.
    • “Only appliances with the WebDialer service enabled are vulnerable, Cisco says. The service is disabled by default.”
  • Cybersecurity Dive adds,
    • “Researchers say a critical vulnerability in Oracle E-Business Suite is facing exploitation attempts by a threat actor. 
    • “The vulnerability, tracked as CVE-2026-46817, is a flaw in the Oracle Payments, and has a severity score of 9.8. 
    • “If successfully exploited, an unauthenticated attacker with network access via HTTP would be able to compromise the product. 
    • “Researchers at Defused observed a hacker exploiting the flaw on its Oracle E-Business honeypots, according to a post on X. The activity was observed on June 27 from a French IP address, but researchers said the threat actor was using a VPN. 
    • “There has been no prior known exploitation activity or any release of a proof of concept, researchers said.” * * *
    • “Oracle previously addressed the vulnerability as part of a larger series of security patch updates in May.”

From the ransomware front,

  • Dark Reading reports,
    • The initial access broker (IAB) operation behind the credential-harvesting FortiBleed campaign is working in concert with ransomware actors, indicating the victims of the massive operation are now facing an even greater threat.
    • Research published by SOCRadar this week connects FortiBleed actors with two ransomware-as-a-service (RaaS) gangs, Inc Ransom and Lynx. SOCRadar researchers discovered an operator behind the campaign’s infrastructure that was actively logged into the ransom negotiation panels for both groups, and “engaging directly with ransom demands.”
    • “Finding a single operator working both panels, using infrastructure traceable back to FortiBleed, is the clearest evidence yet that FortiGate credentials harvested through this campaign are being handed off, or used directly, for ransomware deployment,” according to the SOCRadar blog post
    • “The connection to ransomware gangs marks the latest development in this saga. The attacks against insecure Fortinet FortiGate firewalls were initially discovered last month by security consultant Volodymyr “Bob” Diachenko. SOCRadar then later found that the attacks were part of a global campaign it dubbed “FortiBleed,” which had compromised thousands of devices and used a Golang-based sniffer to turn firewalls into credential stealers.”
  • and
    • “An emerging ransomware campaign is targeting small businesses across multiple regions with fake Interpol notices designed to trick victims into downloading malware disguised as evidence of alleged criminal activity.
    • “The campaign has so far has targeted businesses in multiple sectors, including pharmaceuticals, food, agriculture, technology, media, and legal services in the US, Europe, Asia, and the Middle East.
    • “Besides its focus on small businesses, the campaign is notable because it highlights how attackers no longer need sophisticated ransomware or the resources of a major cybercrime operation to launch disruptive attacks, Bitdefender said in a report this week. “Even relatively simple malware can become a serious threat when paired with convincing social engineering,” Bitdefender security analyst Alina Bizga wrote.”
  • The Hacker News relates,
    • “Security firm Sysdig says it has found what it believes is the first ransomware attack run from start to finish by an AI agent.
    • “Its Threat Research Team calls the operator JADEPUFFER and says a large language model handled the whole job: breaking in, stealing credentials, moving deeper into the network, then encrypting and wiping a company’s production database.
    • “Ransomware has always needed a skilled person somewhere in the loop, either at the keyboard or writing the script the malware follows. If a model can chain those steps on its own, the skill needed to run an attack drops to whatever it costs to rent an AI agent.”
    • “The way in was an old, already-patched bug. JADEPUFFER exploited CVE-2025-3248, a missing-authentication flaw in Langflow, an open-source tool for building AI apps and agent workflows. The flaw lets anyone who can reach the server run their own Python code on it, no login needed.” * * *
    • “The fixes are familiar. Patch Langflow and never expose its code-running endpoints to the internet. Do not run AI tools with cloud keys and provider credentials sitting in their environment; keep secrets in a proper manager, away from anything the web can reach.
    • “Harden Nacos: change the default signing key, keep it off the public internet, and never let it connect to its database as root. Never expose a database’s admin account to the internet, and lock down outbound traffic so a hacked server cannot phone home.”
  • Cyberscoop explains,
    • “How ransomware syndicates weaponize corporate-style organization
      • “From outsourced labor to tiered pricing models, an inside look at how today’s top ransomware threats operate less like rogue hackers and more like Fortune 500 companies.”
  • Cybersecurity Dive informs us,
    • “A massive credential-harvesting campaign, dubbed FortiBleed, is linked to two ransomware-as-a-service operations, tracked as INC ransom and Lynx, according to a blog post Wednesday [July 2, 2026] by cybersecurity firm SOCRadar. 
    • An operator with access to FortiBleed infrastructure was found to be logged into negotiation panels for INC as well as Lynx, researchers said. 
    • In certain cases, the attacks may have involved exploitation of a vulnerability in a content collaboration platform called Nextcloud. The analysis is still ongoing, so a public advisory or common vulnerabilities and exposures number has not yet been assigned. 
    • “The Nextcloud issue appears to have been used as part of the attackers’ broader operational workflow, likely for expansion or infrastructure access after initial compromise,” Ensar Seker, CISO at SOCRadar, told Cybersecurity Dive.
    • “Not all cases involved Nextcloud, nor was compromise fully dependent on exploitation of the zero day.” 

From the cybersecurity business and defenses front,

  • The Wall Street Journal reports,
    • “Chinese artificial-intelligence systems have matched the performance of Anthropic’s powerful model Mythos in some cybersecurity scenarios, a development poised to reset the global tech race and pressure the White House in its overhaul of U.S. AI policy.
    • “Security researchers said that a new AI model, released this month by China’s Zhipu AI, also known as Z.ai, can match the latest U.S. models when it comes to finding security bugs, although it still lags behind Anthropic’s and OpenAI’s products in other tasks.
    • “Overall, the capability gap between top U.S. models and those built by Chinese companies has narrowed significantly, and use of Chinese AI systems has surged as businesses seek to rein in runaway costs. A host of companies, including Microsoft, are weighing how they can offer Chinese models on their platforms, a development that is set to alter the balance of power among tech companies.
    • “China is making sure that the gap becomes smaller and smaller over time,” said Lior Div, chief executive officer of the cybersecurity company 7AI.”
  • Dark Reading relates,
    • “Red Hat and its parent IBM have committed an eye-popping $5 billion to Project Lightwell, a new subscription-based patching service for enterprises running business-critical systems that can’t risk the disruption of updating open-source software in production. It is the largest known commitment specifically targeting open-source software supply chain security — dwarfed only by Google’s broader $10 billion cybersecurity pledge in 2021, which also covered zero-trust and workforce training.”
  • and
    • “Apple is changing its approach to security patching, in response to the growing threat of accelerated artificial intelligence (AI) attacks.
    • “The company has historically saved big, bundled sets of bug fixes for new versions of its operating system (OS). That’s set to change. The company released a variety of security updates June 29 for iPhones, iPads, Macbooks, and the Safari browser, untethered to any major version releases. It’s hardly the first time it’s released security updates out-of-band, but the motivation was different this time. According to Reuters, the company said “it was adapting to the reality that, given the ability of artificial intelligence to speed the development of malicious hacking tools, it ⁠needed to reduce the time between when updates were first made public and when they were put into customers’ hands.”
  • Tech Target discusses “The agentic AI ‘lethal trifecta’: What CISOs should know.”
    • “The very capabilities that make an AI agent useful also make it dangerous. Here’s what CISOs should know about the agentic AI lethal trifecta, and what they should do about it.”
  • Security Week explains “How to Conduct a Successful Audit of AI-Driven Software Development.”
    • “As AI-generated code becomes commonplace, CISOs need new audit strategies to measure developer practices, govern AI tool usage, and identify software risks before they reach production.”
  • Here’s a link to Dark Reading’s CISO Corner.

Pre-holiday weekend report

Simplicity is a virtue

Note — The FEHBlog will be writing his weekly cybersecurity report tomorrow and will resume regular FEHBlog posts on Sunday July 5. Happy Independence Day! We are so blessed to be Americans.

From Washington, DC,

  • Roll Call reports,
    • “As America gets ready to celebrate its 250th birthday, Congress is taking a road trip back to the place where it all began — Independence Hall in Philadelphia. 
    • “Led by Pennsylvania Democratic Rep. Brendan F. Boyle, members will gather for a ceremonial event Thursday in his hometown, an effort Boyle said was two years in the making. 
    • “This is going to be truly one of the highlights of my tenure in Congress, to be sitting there where our Founding Fathers sat exactly 250 years prior, to the exact day,” Boyle said, adding he hoped it could be a rare “unifying moment.” 
    • “While July 4 gets most of the fanfare, Boyle said its lesser-known neighbor, July 2, deserves more attention as the day the Second Continental Congress voted to declare independence from Great Britain in 1776. 
    • “It was always the date that John Adams thought would be celebrated as America’s birthday. Unfortunately, this was another instance in which Adams lost to [Thomas] Jefferson — because Americans came to, of course, celebrate two days later the Fourth of July, which is the date Congress adopted the Declaration of Independence,” he said.” 
  • OPM Director Scott Kupor added a third post (OPM.gov link) to his Secrets of OPM blog this week. In this post, Director Kupor commemorates the new paperless federal retirement system by spurning the altar of Michael Scott, the fictious paper czar of Scranton, PA.
  • Healthcare Dive reports,
    • “The CMS proposed a rule on Thursday that would slash Medicare payment rates for a program [known as 340B] that hospitals use to buy discounted drugs and implement site-neutral payments for some imaging services next year.
    • Reforming the 340B drug discount program and better equalizing payments between sites of care have been priorities in the second Trump administration. Thursday’s proposed rule builds upon those agendas, including by expanding the services subject to site-neutral payments and more aggressively tamping down on discounts given to hospitals in the 340B drug program, which regulators previously tried to overhaul before dialing down their efforts in the face of opposition from the industry.
    • Medicare officials said the proposed rule would control costs and ensure Medicare money is directed toward “clinically appropriate” care. * * *
    • “The 2027 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center rule proposes to increase pay for outpatient care by 2.4%, slightly less generous than the 2.6% rate update finalized last year.
    • “The rule would request information from stakeholders about how hospitals post publicly available price data, an ongoing priority for the Trump administration. Additionally, if finalized, the rule would allow certain accrediting organizations to assess hospitals on their compliance with laws regarding emergency care.”
  • The American Hospital Association News tells us,
    • “The House Education and Workforce Subcommittee on Health, Employment, Labor and Pensions July 1 examined whether direct health care contracts between employers and providers could help address rising health care costs. During the hearing, lawmakers from both parties expressed interest in arrangements that bypass traditional insurers, with supporters citing lower costs, reduced administrative burdens and improved access to care. Witnesses highlighted advantages such as simplified billing, price transparency and direct primary care services, while lawmakers also discussed the need for greater insurer transparency and access to health plan data. The committee did not signal specific legislative proposals following the hearing.”
  • and
    • “The Trusted Exchange Framework and Common Agreement Recognized Coordinating Entity published updated standard operating procedures for the individual access services exchange protocol and new FAQs. The revised SOP removed references to “TEFCA IAS Consent” workflows and associated patient matching methodologies, retaining the ability for providers to verify requests for access and use of data. Updates were made based on recommendations that the AHA and other stakeholders provided to SOP proposals. The SOP will be effective Aug. 3, 2026.”

No Surprises Act news

  • Federal Hearings and Appeals Services, which is certified IDR entity, tells us about
    • “The Cooling Off Period: What Providers and Health Plans Need to Know
      • “What is actually changing with the cooling off period under the final rule for the federal IDR program? To help clarify both the ongoing rules, the coming changes, and their timing, FHAS is offering two new tools to support parties.
        • “First, a new guide to the cooling off period explains which claims are subject to the cooling off period, how long it lasts, what will change under the final rule, and when those changes are coming.
        • “Second, FHAS has launched a new Cooling-Off Calculator which parties can use today to determine cooling off period dates and new dispute initiation timeframes. FHAS can help your team understand, anticipate, and implement changes directed by the final rule.”

From the judicial front,

  • Healthcare Dive reports,
    • “Elevance is suing the CMS after the agency recalculated the Medicare Advantage star ratings of a competitor in a more favorable way than it did for other plans.
    • “After losing a lawsuit earlier this year, the CMS reran 2026 quality scores for Clover Health, dropping 20 measures that a judge ruled could not be factored in. Regulators then recalculated stars for other MA insurers last month, but cut out extra measures, too — measures that Elevance performed well on, the insurer argued in its complaint filed Wednesday in Georgia district court.
    • “Elevance says it lost out on $115 million in bonus payments as a result. The company is asking the court to force CMS to redo its own ratings using the same methodology as for Clover.”
  • STAT News relates,
    • “In a victory for the pharmaceutical industry, a federal judge blocked a Colorado state panel from placing a cap on the price of a blockbuster drug sold by Amgen after deciding the company is “likely to be significantly harmed.”
    • “The ruling pauses a controversial, first-in-the-nation move by the Colorado Prescription Drug Affordability Board, which was created four years ago in response to the rising cost of prescription medicines and is permitted to set upper payment limits on what most state residents will pay for selected drugs.” * * *
    • “Last October, the board then voted to limit what health plans in the state will pay for the drug. The board capped Enbrel prices at $600 for a ​50-milligram weekly dose, or $30,350 a year per person, effective on January 1, 2027. That compared with roughly $53,000 that the average plan in the state paid in 2023, according to a state claims database.
    • “The drugmaker then quickly filed a second lawsuit, reiterating its earlier arguments. Meanwhile, the company had until July 5 to decide whether to continue selling the treatment, which has a list price exceeding $100,000 a year and generated $2.23 billion in sales last year, in Colorado.
    • “But Judge Daniel Domenico of the U.S. District Court in Denver agreed with the company. In his ruling, which was issued on Wednesday, he noted that the state has a ​legitimate interest in helping patients afford Enbrel, but “capping the price of a patented drug” is not an ​option.”

From the public health and medical / Rx research front,

  • The Wall Street Journal reports,
    • “The U.S. overall death rate in 2025 fell to its lowest point on record, even as influenza and pneumonia are now among the nation’s top 10 causes of death for the first time in years, according to new data from the Centers for Disease Control and Prevention.
    • “The death rate fell 4.6% last year, to 689.2 deaths per 100,000 people, down from 722.1 in 2024, according to the CDC’s National Center for Health Statistics. The death rate declined across every age group and nearly every demographic group tracked in the provisional report.
    • “The main driver of the record low was a continued drop in drug overdose deaths, said Farida Ahmad, a health scientist at the CDC and one of the report’s co-authors. Another factor, she added, was that Covid-19 no longer contributed to as many deaths.
    • “Against that backdrop, influenza and pneumonia stood out—moving from 11th to eighth place in all age groups—with 56,511 deaths in 2025 compared with 48,139 in 2024. It is the first time the influenza category has cracked the top 10 since 2020.”
  • AAMC relates,
    • “Patients arrive in the emergency department (ED) doubled over in pain and retching uncontrollably, a brew of symptoms physicians have nicknamed “scromiting” — a combination of screaming and vomiting. The problem: an underrecognized consequence of cannabis use called cannabinoid hyperemesis syndrome (CHS), and emergency medicine physicians say few conditions leave patients more obviously miserable.
    • “My heart breaks for them,” says Kathleen Clem, MD, an emergency medicine physician at Dartmouth Health in Lebanon, New Hampshire, and interim associate dean for faculty affairs at the Geisel School of Medicine at Dartmouth. “They come in because they absolutely cannot keep anything down. They’re dehydrated and their belly is sore from vomiting so much. Sometimes they vomit so much, they’ll break little blood vessels in their esophagus, and little bits of blood come up with that.”
    • “The leading cause of marijuana-related ED visits, CHS is associated with the chronic and long-term use of marijuana products, and it is becoming more prevalent, likely due to the increased legalization of marijuana. Some 24 states have legalized recreational marijuana use since 2012, and 40 states allow its use as a medicinal treatment. An additional eight states allow “limited-access” medical cannabis, which refers to low-THC (tetrahydrocannabinol) products and CBD (cannabinoid) oil.
    • “In the United States, cannabis use has nearly doubled in the past decade, with 22.3% of individuals 12 years and older — 64.2 million people — reporting its use in the past year, up from 12.6% in 2013, according to data from the Substance Abuse and Mental Health Services Administration. And research shows a 15-fold increase in the number of people reporting daily or near daily cannabis use from 1992 to 2022.”
  • The Today Show adds,
    • “Cyclosporiasis, a nasty parasitic infection that causes “explosive” watery diarrhea, has sickened dozens of people in Michigan and other parts of the United States.
    • “Cases of the gastrointestinal illness, caused by a parasite that spreads through contaminated food, have been on the rise in multiple states since May, according to the U.S. Centers for Disease Control and Prevention. At least 20 people have been hospitalized nationwide so far. 
    • “The CDC is working to identify potential sources of the parasitic infection, which is commonly linked to fresh produce.” * * *
    • “The U.S. typically sees several hundred cases of cyclosporiasis annually. In recent years, the number of infections reported in the U.S. has increased significantly.” * * *
    • “The best way to prevent infection is to avoid consuming food or water that may be contaminated with feces, the CDC says. Following proper hand hygiene and safe food handling practices can also lower your risk of foodborne illness.”
  • The New York Times points out,
    • Habitual users of fentanyl have developed such a strong tolerance to the drug that standard doses of medications to manage withdrawal and initiate recovery are no longer working for many patients, a team of researchers in Los Angeles has found.
    • Their study, published in the journal Drug and Alcohol Dependence, presents a picture of the dangerous volatility of the city’s street supply and the capacity of users to tolerate ever greater amounts of pure fentanyl, which is at least 50 times more potent than heroin.
    • “In a summary of the findings, Morgan Godvin, one of the lead authors of the study and a health services researcher at the University of California, Los Angeles, said that a seasoned user’s daily street dose of fentanyl was roughly equivalent to 1,250 hospital doses of 100 micrograms of fentanyl given during and after surgery.
    • “In any other context, that would be unsurvivable,” she wrote. “Among people who use fentanyl every day, it is routine.”
    • “The study reinforces the belief among many addiction experts that, for high-tolerance patients, the standard treatment regimens for opioid addiction have become outdated. Doses of medications such as buprenorphine and methadone, opioids that help satisfy cravings without inducing a high, were calculated to treat addictions to heroin and prescription painkillers. The results of the new research, experts said, support a growing call by clinicians for treatment guidelines to be revised to keep pace with the convulsive drug market.”
  • MedPage Today tells us,
    • “A global study showed that body mass index-associated gaps in blood pressure and cholesterol have diminished from 1990 to 2024.
    • “With more medications being used, older people with obesity were metabolically similar to, and in some countries even lower risk than, people with a normal BMI.
    • “Young adults with obesity remain metabolically higher risk, however, and should be a focus of prevention and treatment, some say.”
  • Genetic Engineering and Biotechnology News informs us,
    • “For nearly half a century, scientists have known that malaria parasites force their way into human red blood cells (RBCs) through a ring-shaped structure called the moving junction (MJ). What no one could work out was what it actually does. The structure assembles, does its job, and dissipates in the space of 60 seconds—gone before anyone can get a close look.
    • “A team at Columbia University has now finally caught the moving junction in the act. By freezing parasites at the onset of invasion and lifting the intact complex straight out of the cell, the researchers obtained the first high-resolution view of its three-dimensional structure. What they saw overturned a decades-old assumption about how the parasite gets in. Rather than a passive doorway, the moving junction turns out to be a molecular machine that actively remodels the host cell’s membrane to help the parasite force its way inside.
    • “The findings detail how the team obtained the structure and then used it as a blueprint to design a mini-protein, from scratch, that blocks invasion—a proof of concept for a new kind of antimalarial drug.”
  • The Washington Post lets us know,
    • “When it comes to dementia risk, certain factors, such as genetics, are out of your control. However, plenty of research suggests lifestyle behaviors— things you can change — may help improve your chances of staying sharp as you age. In a new study, people with an elevated risk of dementia were less likely to develop the condition if they followed a healthy dietary pattern, particularly a less inflammatory one.”
  • Per BioPharma Dive,
    • “Roche’s experimental medicine divarasib helped patients with a certain type of lung cancer live longer than two approved treatments in a new study.
    • “The Phase 3 trial compared divarasib with Amgen’s Lumakra and Bristol Myers Squibb’s Krazati in patients with KRAS G12C non-small cell lung cancer who had already received previous treatment. Researchers found significant improvements in both overall survival and progression-free survival for the group taking divarasib, Roche said Thursday.
    • “Roche did not release detailed data, saying the results would be presented at an upcoming medical meeting. There were no new safety findings of concern and most treatment-related side effects were “manageable and reversible,” the company said.”

From the U.S. healthcare business front,

  • Healthexec reports,
    • With Election Day only four months away, healthcare is again emerging as a major source of idealistic campaign promises. Many of these are driven by widespread public angst. What sorts of changes can U.S. healthcare stakeholders realistically expect once the results are in? 
    • “Professional prognosticators at the global accounting and consulting firm PricewaterhouseCoopers, aka PwC, have considered the policy possibilities and are sharing their thinking in writing. * * * PwC offers forward-looking insights and advice for organizations across healthcare’s four major subsectors. 
      • PROVIDERS: Policy drivers are reshaping delivery and access. 
        Healthcare providers will do well to “examine their care delivery footprints, leverage automation and technology to reimagine the workforce and operations in order to mitigate economic strain,” PwC comments. 
        ‘This should include identifying opportunities to diversify revenue sources, partnerships or M&A with other stakeholders, and prioritizing investment in new technology to reduce impacts of the increase in uncompensated care and workforce constraints.’
      • PAYERS: Policy drivers are reshaping cost structures. 
        “Healthcare payers will likely need to strengthen care management capabilities as they expand their holistic support to members, the analysts forecast. 
        ‘This will include, in the future, leveraging sophisticated data models and interactive real-time communications to understand and influence member behavior patterns, accelerate paths to appropriate cost-effective care, and drive financial savings for members and plans.’
      • PHARMA: Policy drivers are reshaping pipeline decisions, regulatory strategy and market access. 
        “In the future, pharmaceutical manufacturers, propelled by accelerating science and shifting patient expectations, “should expand from drug manufacturers to ‘lifespan partners,’ requiring more agile operating models and greater collaboration across technology, and ecosystem players,” the authors write.  
        ‘In the interim, pharmaceutical manufacturers can embrace innovative approaches to access, affordability and evidence generation to meet the needs of today’s consumer and keep pace with pipeline and pricing pressures.’
      • MEDTECH: Policy drivers are reducing federal oversight of AI-powered and wellness devices. 
        “Going forward, the subsector is expected to become a broader ecosystem player, building interoperable, intelligent systems that connect care across hospitals and the home, PwC remarks. 
        ‘MedTech should strengthen capabilities for post market surveillance as FDA shifts oversight focus from a premarket review paradigm to an emphasis on performance and safety once on the market, particularly for low risk, consumer devices.’
  • Cardiovascular News relates,
    • “The American College of Cardiology (ACC) reached a major milestone this summer; its highest honor, the HeartCARE Center National Distinction of Excellence, has officially been awarded to 100 U.S. hospitals [all of which are listed in the article]. 
    • “The ACC established the HeartCARE Center designation in 2018 to celebrate hospitals and health systems that “demonstrate ongoing excellence through comprehensive accreditation, data-driven performance measurement and continuous quality improvement initiatives.” Recipients must be “forward-thinking organizations” that participate in ACC Accreditation Services programs, NCDR registries and other quality improvement campaigns focused on cardiovascular health.
    • “Reaching 100 hospitals recognized as ACC HeartCARE Centers marks an important milestone in our ongoing effort to elevate the standard of cardiovascular care,” Steven B. Deitelzweig, MD, chair of the ACC Accreditation Oversight Committee, said in a statement. “Each of these institutions has demonstrated a deep commitment to evidence-based care, continuous quality improvement and measurable outcomes—ensuring that patients receive the highest level of cardiovascular care, no matter where they live.”
  • Beckers Hospital News tells us,
    • “The Kroger Co. will acquire supermarket chain Giant Eagle, Inc. for $1.65 billion, expanding its pharmacy footprint across northern Ohio, western Pennsylvania, West Virginia, Maryland and Indiana.
    • “Giant Eagle operates 11 standalone pharmacies, according to a July 1 news release. Kroger said the acquisition will strengthen its presence in adjacent markets and build on Giant Eagle’s pharmacy business, loyalty program and private label portfolio. 
    • “The deal adds to Kroger’s pharmacy footprint at a time when retail pharmacy access is contracting elsewhere in the industry, with Walgreens restructuring into five standalone companies following multibillion-dollar operating losses and Rite Aid’s footprint largely gone — a gap health systems have increasingly stepped in to fill by opening their own pharmacies.” 
  • MedTech Dive informs us,
    • “Guardant Health said Wednesday its Shield test for colorectal cancer is now covered by UnitedHealth, the first major private U.S. health insurer to reimburse for the screening.
    • “The decision by UnitedHealth, the largest private U.S. health insurer, expands access to the screening to about 100 million Americans, the company said.
    • “Canaccord Genuity analyst Kyle Mikson, in a note to clients, called the coverage decision a “watershed moment” for liquid biopsy-based cancer screening and for the category of blood-based cancer testing.”

Wednesday report

Simplicity is a virtue.

HAPPY NATIONAL POSTAL WORKERS DAY!

From Washington, DC,

Plenty of news from the U.S. Office of Personnel Management today.

  • Per an OPM news release,
    • “Today, the US Office of Personnel Management (OPM) announced the “Last Day of Paper,” officially ending paper retirement processing for more than 95 percent of federal retirement applications and completing the agency’s transition to a fully digital retirement process.
    • “For decades, federal retirement applications relied on a paper-based process that required physical documents to move between agencies, payroll providers, and OPM’s Retirement Operations Center in Boyers, Pennsylvania. As of yesterday, nearly all retirement applications will be submitted and processed electronically through OPM’s Online Retirement Application (ORA), eliminating paper from the process and significantly reducing processing times.
    • “The milestone follows rapid adoption of ORA, which has processed more than 155,000 retirement applications over the past year after serving only a few hundred users during its initial rollout.” * * *
      • “As part of today’s milestone, OPM is also launching new capabilities designed to accelerate retirement processing, including:
      • “A new pre-retirement application that allows employees and agency HR offices to complete much of the retirement process before an employee’s separation date.
      • “Earlier processing of retirement applications while final payroll information is still being finalized, reducing unnecessary delays.
      • “A commitment to issue a retiree’s first pension payment within seven days of retirement for applicants who submit a complete retirement package by their separation date.”
  • FEHBlog observation – While OPM deserves credit for this accomplishment, the agency has not announced implementing the HIPAA standard transaction 820 which is an electronic enrollment roster that would allow carriers to reconcile premiums to individual enrollments. The HIPAA 820 has been around since 2012. Carrier systems must accept the HIPAA 820. What is the sense in collecting family member eligibility documents when no one currently knows whether the enrollee is paying the proper premium?
  • Govexec adds,
    • “The federal government’s 401(k)-style retirement savings program posted mixed results in June, ending two straight months of consistent growth.
    • “The Thrift Savings Plan’s S Fund, which is made up of small- and mid-size businesses, saw the best performance, gaining 4.34% last month. Since January, the S Fund has grown 18.41%.
    • “The fixed income (F) fund increased 0.25% last month, bringing its 2026 performance to 0.74%. And the G Fund, which is made up of government securities, increased by its statutorily mandated rate of 0.37%. So far this year, the G Fund has swelled 2.18%.
    • “But the I Fund was virtually flat in June, losing 0.03%. That brings the I Fund’s 2026 performance to 16.53%. And the C Fund’s common stocks fell 0.95%, bringing its gains since January down to 10.20%.”
    • The performance of other funds can be found in the article.
  • Another OPM news release tells us,
    • “The US Office of Personnel Management (OPM) today proposed sweeping reforms to modernize how agencies address poor performance, streamline disciplinary and removal procedures, and strengthen accountability across the federal workforce.
    • The proposed rule would require agencies to better equip supervisors with training on employee accountability while making it easier to address employee performance issues. Among other reforms, the proposal establishes a default 30-day Performance Improvement Plan (PIP), eliminates pre-PIPs that unnecessarily delay action, standardizes employee response periods for adverse actions, and modernizes Merit Systems Protection Board review of adverse action appeals by replacing the current checklist-based approach (called “the Douglas factors”) with a totality-of-the-circumstances standard.
    • This proposal is part of the Trump Administration’s broader effort to build a high-performing federal workforce that rewards excellence, recognizes strong performance, and holds employees accountable when performance falls short.” * * *
    • “The proposed rule will be published in the Federal Register and will be open for public comment. Read Director Kupor’s blog post on this here.”
  • OPM Director Scott Kupor added a second post to this Secrets of OPM blog today. The second post is titled “Measure what matters.”
    • “Last year, we postponed the Federal Employee Viewpoint Survey (FEVS) and critics were quick to claim that we at OPM did not believe in employee engagement surveys. That couldn’t be farther from the truth. * * *
    • So, today we announced that OPM will no longer centrally administer FEVS. As a centrally-administered system, it’s costly, doesn’t serve as a valuable management tool and fails to enable actionable results. That serves nobody well.
    • Instead, we have provided detailed guidance to agencies on how best to design surveys that meet their specific needs. That guidance includes a common set of core questions that every agency will ask—ensuring we preserve the ability to track government-wide trends and maintain a coherent thread of data across the federal workforce. The goal isn’t fragmentation; it’s better ownership. Agencies will have the flexibility to go deeper where their missions demand it, while OPM retains the visibility to understand the broader landscape and identify where systemic challenges require government-wide attention.”
  • Federal News Network reports,
    • “President Donald Trump said Monday [June 29] he will nominate Keith Sonderling to be the secretary of labor, elevating him from the agency’s acting director two months after Lori Chavez-DeRemer resigned amid abuse-of-power allegations.
    • “Sonderling, a lawyer who has held a variety of acting positions and leadership roles across Trump’s government, was previously the deputy labor secretary and a Republican member of the Equal Employment Opportunity Commission.
    • “Throughout his career, Keith has proven his dedication to delivering strong results for the Hardworking People of our Country, and I know he will do an incredible job in his new role,” Trump wrote in a Truth Social postannouncing Sonderling’s nomination.
    • Sonderling’s nomination is subject to Senate confirmation.
  • Fierce Healthcare relates,
    • “The Trump administration has officially launched its new “bridge” model that brings GLP-1 coverage for weight loss to Medicare beneficiaries.
    • “Eligible people enrolled in Medicare Part D can secure certain GLP-1 medications for weight loss or management at $50 each month. The program will remain in place through the end of 2027, the Centers for Medicare & Medicaid Services said in an announcement.
    • ‘Under the GLP-1 bridge, the feds will cover the cost of expanded coverage. Alongside this model, the agency also proposed a second approach—called Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, or BALANCE—in which it would negotiate lower GLP-1 prices in exchange for standardized coverage options.
    • “Plans balked at the model, and CMS indefinitely delayed from a planned January 2027 start date. A similar model was implemented in Medicaid in May 2026.
    • “In a CMS announcement commemorating the model’s launch, Administrator Mehmet Oz, M.D., urged beneficiaries to reach out to their doctors to see if they’re eligible.
    • “For too long, many Americans have been unable to access these treatments because of cost,” Oz said.”
  • Per a CMS news release,
    • “The Centers for Medicare & Medicaid Services (CMS) is proposing new safeguards to ensure taxpayers aren’t on the hook for noncompliant Medicare providers and suppliers, continuing its campaign to crush fraud, waste, and abuse throughout its programs and hold bad actors accountable. The Calendar Year (CY) 2027 Home Health Prospective Payment System (PPS) proposed rule would strengthen CMS’ ability to recover improper payments and remove non-compliant providers and suppliers from Medicare, actions estimated to save approximately $82 million in annual savingswhile also expanding access for patients receiving care at home and improving the timeliness of publicly reported home health agency quality information.”
    • * * * “The proposed rule also would update Medicare home health payment rates for CY 2027. At the same time CMS is strengthening oversight and crushing fraud, waste, and abuse, the agency is proposing targeted payment updates that support access to care for beneficiaries who rely on home health services. CMS is also proposing to continue to fulfill its statutory obligation to transition the Home Health PPS to the Patient-Driven Groupings Model in a budget-neutral manner. CMS estimates total Medicare payments to home health agencies would increase by approximately 2.4%, or $420 million, compared to CY 2026.” * * *
    • “To view a fact sheet on the proposed rule, visit: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-home-health-prospective-payment-system-proposed-rule-fact-sheet-cms-1844-p
    • “The proposed rule can be viewed on the Federal Register at: https://www.federalregister.gov/d/2026-13602.” 
       
  • Per a GAO news release,
    • “A leading cause of death in the U.S., suicide resulted in more than 49,000 deaths in 2023. That’s up by 31% from 2003.
    • “To help those at risk, the federal government set up the 988 Suicide & Crisis Lifeline. It offers support via call, text, and chat.
    • “Since the Lifeline’s inception in July 2022 through September 2025, we found:
      • “Call, text, and chat contact volume increased
      • “Call answer rates increased, while text and chat answer rates varied
      • “Average time to answer calls, texts, and chats varied
    • “We also found that the federal government set goals for the Lifeline. It collected data related to those goals and used it to assess its performance.”
  • HR Dive points out,
    • “The U.S. Equal Employment Opportunity Commission rescinded its affirmative action guidelines Tuesday, eliminating an interpretation that had persisted for 40 years.
    • “According to a June 30 statement, the guide and a related compliance manual “ran afoul” of Title VII of the Civil Rights Act of 1964 and more recent U.S Supreme Court rulings in the eyes of the commissioner. Almost three years ago to the day, the high court issued its decision in Students for Fair Admissions, Inc. v. Harvard, holding that race-conscious admissions practices at two universities were unconstitutional.” * * *
    • “The takeaway from the new plan should not be to “abandon lawful EEO efforts, but to ensure policies do not use protected characteristics as selection criteria,” management-side attorney Randi Hyatt, a partner at Whiteford, Taylor & Preston, said in an analysis.”

No Surprises Act News

  • Fierce Healthcare reports,
    • “Healthcare technology company Zelis rolled out an AI-native solution to help health plans manage Independent Dispute Resolution complexity under the No Surprises Act.
    • “Independent Dispute Resolution (IDR) is the process for adjudicating out-of-network claims created by 2020’s No Surprises Act (NSA).
    • “Zelis’ solution uses AI to automate payers’ workflows, from claim repricing, open negotiation, dispute prevention, case management and IDR resolution. The company unveiled the new solution as dispute volume, compliance requirements and process deadlines pressure payer operations, executives said.”

From the Food and Drug Administration front,

  • Per an FDA news release,
    • The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT). This is the first gene therapy approved for patients aged 2 years and older with SCD.  
    • Casgevy has been previously approved for the treatment of patients aged 12 years and older with SCD with recurrent VOCs or TDT.  
    • “With today’s decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER). “The FDA is committed to prioritizing and speeding up the review of products that address critical U.S health priorities through expedited review programs, including the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program. These initiatives are designed to advance therapies for diseases with significant unmet medical needs, enabling faster access to innovative treatments while upholding the FDA’s rigorous gold-standard requirements for safety and effectiveness.”  
  • Per an HHS news release,
    • “The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) today commended the Drug Enforcement Administration’s (DEA) issuance of two Notices of Intent to begin the temporary scheduling process for certain kratom-related substances.
    • ‘One Notice of Intent addresses temporary placement of 7-OH above a specified threshold in Schedule I, while the second would temporarily place three synthetic 7-OH derivatives into Schedule I of the Controlled Substances Act (CSA):
      • “Mitragynine pseudoindoxyl (MP)
      • “Dihydro-7-hydroxymitragynine (MGM-15)
      • “The 9-fluoro derivative of 7-hydroxymitragynine (MGM-16)
    • “Concurrent with DEA’s Notice of Intent addressing 7-OH, the Office of the Assistant Secretary for Health (OASH) issued a Request for Information (RFI) on seeking public comment on the proposed 7-OH threshold level in the NOI. The request is limited to obtaining comments on whether: 1) there is additional scientific data to support the proposed or an alternative threshold level – specifically, what concentration or quantity of 7-OH in a product constitutes an imminent hazard to public safety; and 2) data exist supporting alternative measurement expressions for purposes of specifying the threshold level that is necessary to avoid an imminent harm to public safety.
    • “After the 30-day comment period for the RFI, OASH will provide comments submitted to the RFI public docket to the Attorney General for consideration. Once comments have been considered and at least 30 days have passed since the publication of the NOI, the Attorney General may then issue a temporary scheduling order placing 7-OH above a certain threshold in Schedule I. The CSA provides the Attorney General with the authority to issue a temporary scheduling order placing a substance in Schedule I of the CSA for two years, if such action is necessary to avoid an imminent hazard to public safety.”
  • Cardiovascular Business relates,
    • “Amgen is recalling nearly 935,000 bottles of ivabradine, a heart failure drug the company sells under the brand name Corlanor, due to the presence of a foreign substance. 
    • “The recall includes specifics lots of 5-mg and 7.5-mg Corlanor tablets manufactured in Italy and then distributed by Amgen throughout the United States. The drugs are packaged in 14- and 60-tablet bottles. Expiration dates range from July 2026 to December 2028.
    • “The U.S. Food and Drug Administration (FDA) has categorized this as a Class II recall, which means taking the drugs in question could cause “temporary or medically reversible adverse health consequences.”
    • “Amgen first received FDA approval for ivabradine in April 2015. The agency’s decision was largely based on data from the SHIFT trial, which included more than 6,500 patients randomized patients treated with ivabradine or a placebo. In 2021, researchers found that ivabradine could be used to treat symptoms associated with postural orthostatic tachycardia syndrome in COVID-19 patients.”
  • MedTech Dive adds,
    • “The Food and Drug Administration has reported 252 injuries were associated with Hologic’s BioZorb radiographic markers implanted in the breast and other soft tissue sites during medical procedures. No deaths were reported.
    • “The update comes almost two years after Hologic told customers to stop using the devices due to reports of adverse events such as pain, infection and device migration. At the time, Hologic said it had received 188 complaints associated with adverse events.
    • “In its latest communication, the FDA repeated Hologic’s instructions advising healthcare providers not to use the BioZorb markers. Patients should be monitored for signs of adverse events, but Hologic said there is no need to have an implanted marker removed from the body.”
  • Beckers Hospital Review tells us,
    • “Cisplatin, carboplatin, oxaliplatin and ifosfamide remain in active shortage, and manufacturers’ latest estimates show full resupply of some formulations will not arrive until October, according to updates posted by the American Society of Health-System Pharmacists. 
    • “The four chemotherapy drugs form the backbone of treatment for breast, lung, ovarian, testicular, bladder, and head and neck cancers. Becker’s previously reported that hospitals and cancer clinics working with group purchasing organization Premier received only 38% of their ifosfamide orders and about two-thirds of their cisplatin orders in recent weeks, prompting some healthcare organizations to space out doses and prioritize patients most likely to benefit from treatment.”
  • BioPharma Dive identifies “5 FDA decisions to watch in the third quarter of 2026.”
    • “A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.”

From the public health and medical / Rx research front,

  • The Washington Post reports,
    • “West Nile virus activity is starting earlier than it has in years, with the CDC warning it is now seeing the highest number of human cases of the nasty mosquito-borne disease since 2004.
    • ‘At least 48 cases had been reported as of Tuesday, and 38 have involved serious illness affecting the brain or nervous system. 
    • “For comparison, by the end of June, the Centers for Disease Control and Prevention usually sees only about 10 human cases. The earlier start could be problematic, as it extends the amount of time people could be exposed to the disease before the season dies down in colder months.” * * *
    • “Arizona has reported the highest number of cases in the country at 32. Maricopa County, the state’s most populous county, has reported 29 cases, including four deaths, already more than half of the case total it reported in all of 2025.”
  • Drug Topics relates
    • “Surveillance through June 2026 shows widespread, outbreak-driven measles transmission, with 93% of cases in unvaccinated/unknown-status individuals and 6% requiring hospitalization. 
    • “Erosion of kindergarten MMR coverage from 95.2% to 92.5% leaves hundreds of thousands susceptible, while subregional coverage can fall near 50%, enabling explosive outbreaks. 
    • “Utah’s large outbreak prompted enhanced monitoring, including wastewater-based detection, and recommendations for earlier MMR dosing (from 6 months) to mitigate infant risk. 
    • “Persistent misinformation and vaccine hesitancy necessitate motivational interviewing techniques (OARS, readiness rulers) and proactive pharmacist-led community engagement to rebuild trust and uptake.”
  • Managed Health Executive points out,
    • “Physical inactivity and racial and ethnic minority status emerged as the two strongest predictors of diabetes prevalence across U.S. counties in a new machine-learning analysis published in Diabetes/Metabolism Research and Reviews.
    • “The cross-sectional study, led by Nicolaas P. Pronk, Ph.D., of the HealthPartners Institute, set out to capture what the authors call the “multilevel ecology” behind diabetes, defined as the mix of broad structural forces and individual-level behaviors that impact diabetes development.”
  • Beckers Clinical Leadership lets us know about “Lung cancer screening, mortality and incidence — by state.”
    • “At 11%, California had the lowest up-to-date lung cancer screening rate in 2024, while Connecticut, Massachusetts and Pennsylvania had the highest rate at 28%, according to American Cancer Society data. 
    • “The national median rate for up-to-date lung cancer screening in 2024 was 18%.
    • “Lung cancer mortality and incidence remain highest in Kentucky and West Virginia, despite having above-average lung cancer screening rates.” 
  • Health Day tells us,
    • “Stepped alcohol treatment (SAT) offered via telehealth helps people with chronic liver disease (CLD) reduce alcohol consumption, according to a study published online June 24 in Hepatology.
    • “Derek D. Satre, Ph.D., from the University of California, San Francisco (UCSF), and colleagues evaluated the efficacy of telehealth SAT, which consisted of three motivational interviewing sessions followed by addiction medicine referral if no drinking reduction at month 3. One hundred fifty-seven adults with CLD and unhealthy alcohol use (>7 drinks/week or ≥4/day for women; >14/week or ≥5/day for men; or heavy episodic drinking) were randomly assigned to SAT (81 participants) or usual care (76 participants). 
    • “The researchers found that SAT had no difference in percentage of alcohol use below moderate level (primary outcome) versus usual care. However, SAT had greater reduction in drinks/week from baseline to month 3 and month 6 (estimates, −0.66 and −0.67, respectively) (secondary outcome). Compared to usual care, the six-month effect of SAT on alcohol use reduction remained significant when controlling for covariates. The 30-day abstinence rates were 29 percent for SAT and 18 percent for usual care at month 6. There was a positive association between baseline motivation to reduce alcohol use and treatment response.”
  • The latest NIH Research Matter covers the following topics:
    • “Alzheimer’s proteins in blood linked to midlife cognition 
      • “A study found that people in midlife with more Alzheimer’s-related proteins in their blood had worse cognitive function.
      • “The results suggest blood tests could one day help identify people who may benefit from early efforts to delay Alzheimer’s symptoms.”
    • Genetic testing may benefit more patients with melanoma 
      • “Researchers found people diagnosed with melanoma at a young age or with multiple melanomas were more likely to carry a genetic mutation.
      • “The findings suggest that certain patients with melanoma could benefit from genetic testing to identify mutations and potential risk for other types of cancer.”
    • Senescent cells mapped in human body over the lifespan
      • “Scientists located and classified senescent cells, a hallmark of aging, to begin building an atlas of these non-dividing cells in the human body.
      • “The atlas could help track how senescent cells drive age-related conditions and may inform treatment strategies for age-related diseases.”
  • The University of Minnesota’s CIDRAP notes,
    • “Vaccine myths are not new. They have circulated for decades, surviving retracted studies and countless public health campaigns. Now, a new poll suggests that, while relatively few Americans fully believe those falsehoods, many remain uncertain about them—a finding that suggests opportunities to counter vaccine misinformation.” * * *
    • “The poll found a strong association between trust in healthcare providers and vaccine attitudes, with adults who have a provider they trust being less likely to believe vaccine myths.
    • “Just under half of adults (46%) who do not have a trusted healthcare provider to answer questions about their health said it was “probably” or “definitely true” that more people have died from COVID vaccines than from COVID itself. That’s almost twice as many as those who reported having a trusted provider (24%). 
    • “Researchers noted that the relationship remained significant even after accounting for factors such as age, race and ethnicity, education, political affiliation, and insurance status.”
  • Per BioPharma Dive,
    • “Shares of Paris-based biotechnology company Abivax surged nearly 40% Tuesday following the release of supplementary Phase 3 data on its inflammatory bowel disease drug that cleared away investors’ concerns about increased cancer risk.
    • “Abivax said cancer rates seen across enrollees in its Phase 2 and Phase 3 trials were no higher than the “background” one seen in people with ulcerative colitis, which is higher than the general population in certain types of malignancies.
    • “The update from the second part of that Phase 3 trial — which enrolled people who didn’t respond to the drug or relapsed during the trial — added safety data that “appropriately addresses the key overhang facing the stock,” wrote Jefferies analyst Faisal Khurshid in a client note. Abivax followed the share price increase with an $800 million sale of its U.S. listed shares.”

From the U.S. healthcare business and artificial intelligence front,

  • Modern Healthcare reports,
    • “Brian Evanko, Cigna Group’s new chief executive officer, said he aims to put patients at the center of the company’s strategy. He’ll have to convince people struggling with rising healthcare costs that he’s serious — and persuade Wall Street that this strategy can be profitable. 
    • “That’s been a difficult balancing act for Cigna. Last year the company announced that it would phase out rebate payments from drug companies in many of its prescription plans, pulling back from a “middleman” practice the Trump administration has criticized.
    • “Cigna said this would lower patient costs and only temporarily shrink profits. But investors punished Cigna with its worst selloff in 17 years. Its shares still haven’t recovered.”
    • “It’s a tension Evanko will have to navigate beginning Wednesday when he becomes the public face of Cigna, a giant in medical insurance, prescription drug benefits and specialized pharmacy services. Insurers are under fire in Washington for high costs. Employer clients are balking at premium hikes. Patients are frustrated with spending-control tactics like prior approvals. And investors are wary that addressing those concerns could erode profits.
    • “Evanko said he’s focused on making Cigna more responsive to the 185 million people who use its healthcare services, the bulk of whom have prescription drug coverage managed by the business.
    • “For me, coming into the role, importantly, we’re going to put the customer at the center of everything we do, so being patient-first,” Evanko, 50, said in a recent interview at Bloomberg’s New York headquarters. “We see that as actually a strategic choice.”
  • Beckers Payer Issues relates,
    • “Hospitals and insurers have been fighting an AI billing war for the better part of two years, with providers deploying the technology to optimize and defend their coding, and payers using it to audit and push back.
    • “AI is placing pressure on cost through RCM tools, and we have seen those patterns in terms of service intensity, and cost per encounter going up,” UnitedHealthcare CEO Tim Noel said at a June media event attended by Becker’s. “It clearly has occurred, and that is a source and driver of trend. I don’t think that that’s going to be persistent. That’s a moment that we’re in that will get to saturation.”
    • “Revenue cycle executives and physicians have described the ongoing dynamic as an “AI arms race,” that has been adding administrative cost and friction on both sides. This month, PwC projected that employers’ medical cost trend will reach its highest level in 17 years in 2027, pointing to provider adoption of AI documentation and coding tools as one of five primary inflators. Nearly 70% of surveyed health plans ranked it among their top three concerns, and roughly 20% named it the single largest driver.
    • “Mr. Noel said UnitedHealthcare is already working to move beyond paid-claims data to understand “more upstream where these hot spots are.” 
    • “The global trends are the global trends, and there are some opportunities to address those in the moment, and we are,” he added. “But we also have to look for new sources of affordability moving forward.”
  • and
    • “Sustainability has become less about cutting costs and more about redesigning how healthcare delivers value. Becker’s asked several health plan leaders how they’re thinking about long-term sustainability, and the responses point to a shared shift away from volume-driven models toward outcomes, accountability, and member-centered design. From shifting social health programs toward measurable, evidence-based interventions to redesigning the consumer experience around choice and transparency, leaders are converging on the idea that sustainability isn’t a single initiative — it’s a durable operating model built for the long haul.
    • “The answers below reflect a range of strategies, from strengthening payer-provider partnerships and embedding AI into clinical decision-making to balancing financial discipline with health equity and community trust. Common threads emerge around reducing low-value care, building data infrastructure that supports proactive rather than reactive management, and designing systems flexible enough to adapt as member needs evolve. [In the article], healthcare leaders share how they’re positioning their organizations for what’s next.
  • Vizient discusses “From scale to orchestration: The new requirements for payer success.”
    • “For executive and board consideration:
      • “Evaluate strategic pathways, including independence, partnership, affiliation, or acquisition.
      • “Assess strengths and gaps across products, member diversification, scale, and market positioning
      • “Identify partners that align across strategy, governance, economics, and long-term objectives.
      • “Execute transactions and integrations with rigor and discipline.”
  • MedCity News considers,
    • “Healthcare’s Most Avoided Question: “How Much Exactly Do You Need, and What Will America Get in Return?”
      • “Before policymakers, employers, insurers, or taxpayers commit ever-larger sums to the system, an uncomfortable question deserves attention: How much additional capacity does healthcare actually need and what measurable outcomes should society expect in return?”
  • Modern Healthcare tells us,
    • “Allegheny Health Network closed its acquisition of Heritage Valley Health despite pushback from the Pennsylvania attorney general. 
    • “The deal adds Heritage’s two hospitals, dozens of clinics and 500 employed and affiliated physicians to the 16-hospital provider division of Highmark Health.
    • “A final order Friday from a federal court paved the way for the transaction’s close, with conditions. Last Wednesday, Pennsylvania Attorney General Dave Sunday (R) sued to block the transaction over potential anticompetitive effects. He claimed the acquisition could allegedly increase hospital and radiation oncology prices in Beaver County and Allegheny County.
    • “The order from U.S. District Court for the Western District of Pennsylvania Judge Maureen Kelly requires Allegheny Health to provide current services at the rebranded AHN Beaver Hospital – Heritage Valley and AHN Sewickley Hospital – Heritage Valley for at least five years and maintain an existing joint venture between Heritage Valley and UPMC Cancer Centers.
    • “In addition, Allegheny cannot terminate automatic renewal clauses in its insurer contracts for at least a year and it must pay Sunday $75,000 in legal fees, among other provisions.”
  • The Wall Street Journal informs us,
    • Ipsen IPN said it agreed to buy Swiss biotechnology company Memo Therapeutics in a deal that could exceed 700 million euros ($799.6 million) and that seeks to expand the French drugmaker’s rare-disease portfolio.
    • “The move marks Ipsen’s second acquisition this week after its agreement to take over Kartos Therapeutics, a company developing a drug to treat a rare blood cancer, for up to $1.75 billion.
    • “Ipsen said it would pay 200 million euros initially and make deferred payments subject to certain development, regulatory approval and sales-based targets that could take the total price above 700 million euros.
    • “The deal focuses on Memo’s experimental drug potravitug for the treatment of nephropathy associated with BK polyomavirus, a complication in kidney transplant recipients, Ipsen said. The drug—which was granted fast-track designation from the U.S. Food and Drug Administration in 2023—is due to move to a mid- and late-stage clinical trial later this year, the company added.”
  • Fierce Healthcare points out,
    • “Patients are taking charge of their healthcare with artificial intelligence and other solutions, with 58% of U.S. patients researching symptoms before deciding whether to book an appointment, according to a new report from ZS Impact Institute. 
    • “The recent report drew insights from nearly 10,000 healthcare consumers and providers across the U.S., Germany and China. Researchers note the shift is consistent across healthcare systems, which they say points to a “broader breakdown in how patients seek and experience care globally.”
    • “Thirty-seven percent of U.S. respondents report using search engines for health information—94% of which find it helpful—and 18% report using AI. Eighty-nine percent of those using AI to find information report it being helpful.”
  • and
    • “Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
    • “Called Pharmacy Forward, the program aims to use technology to drive more coordinated, connected care and to offer personalized supports in real time. Evernorth plans to launch the program first for Accredo Specialty Pharmacy customers, investing $100 million through 2028 in the project.
    • “The goal, according to an announcement from the company, is to allow care teams to spend more time on clinical and patient care, while also accelerating prescription processing and service responsiveness.
    • “Patients navigating complex health conditions need comprehensive, expert support, often during some of the most difficult moments in their lives,” said Matt Perlberg, president of the Evernorth Health Services pharmacy and care delivery businesses, including Accredo, and executive vice president of Customer Innovation for The Cigna Group, in the announcement.”
  • Beckers Health IT notes,
    • “Anthropic is launching an internal drug discovery program with a focus on neglected diseases that traditional pharmaceutical companies would not consider commercially attractive, CNBC reported June 30.
    • “At a June 30 event in San Francisco, Eric Kauderer-Abrams, Anthropic’s life sciences head, said the effort is designed to give the company firsthand experience in drug development as it builds AI tools for biopharma customers. Anthropic leaders framed the drug discovery program as a way to build credibility with the biopharma companies it hopes to win as Claude Science customers.
    • “Jonah Cool, Anthropic’s head of life sciences partnerships, said the focus on neglected diseases will run alongside the company’s broader push to create and sell AI tools to life sciences companies.”
  • Genetic Engineering and Biotechnology News adds,
    • “Anthropic has released Claude Science, an AI workbench for scientists that consolidates fragmented research tools, including over 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer. The platform joins an increasingly crowded ecosystem of tech platforms specialized for biology and aims to accelerate scientific discovery by making domain expertise more accessible.
    • “Anthropic’s life science partners are delivering applications. Basecamp Research is targeting global public health, where drug-resistant infections play a role in nearly five million deaths per year. The London-based team has announced that its antibiotic design and vaccine target prediction EDEN models will now be available through Claude Science.
    • “A metagenomic foundation model, EDEN demonstrated a 97% success rate when designing functional peptides with high potency against World Health Organization (WHO) critical-priority and multidrug-resistant pathogens. The work was done in collaboration with César de la Fuente, PhD, presidential associate professor at the University of Pennsylvania.”

Tuesday report

Simplicity is a virtue.

From Washington, DC,

  • Roll Call reports,
    • “House Republican leaders are giving up on trying to put the pieces back together for a rule needed to take up a raft of pre-recess legislative priorities after a group of GOP rebels blocked the procedural measure earlier, largely over lack of movement on voter ID requirements.
    • “The decision to send members home early for the July Fourth recess after Tuesday afternoon votes came after Speaker Mike Johnson, R-La., huddled in his office with Rules Chairwoman Virginia Foxx, R-N.C., and others on how to reconstruct a path forward.” 
  • Modern Healthcare relates,
    • “A bipartisan House bill would require extensive reporting on private equity firms’ healthcare holdings and ownership structures.
    • “The draft measure could reveal tactics such as sale-leaseback arrangements like those that contributed to Steward Health Care’s bankruptcy.
    • “Some Democrats want to go further than transparency and say enforcement needs to be tougher.”
  • Beckers Hospital Review tells us,
    • “A growing number of states are moving to cap what hospitals can charge commercial payers and employers, turning hospital pricing into one of the most active battlegrounds in state health policy.
    • “Several states enacted hospital price caps in 2025, and the 2026 legislative sessions have brought a fresh wave of proposals tied to Medicare rates, according to The Commonwealth Fund. ” * * *
    • “For now, the cap fight is a state story. The federal government’s lever on hospital prices has been transparency and site-neutral payments, not price ceilings.
    • “CMS finalized price transparency rules requiring hospitals to post median and percentile allowed amounts in their machine-readable files, with enforcement beginning April 1, 2026. In June, the White House warned more than 500 hospitals to post pricing information or face fines. CMS also expanded site-neutral payment policies in its 2026 outpatient rule, aligning some hospital outpatient rates with lower-cost settings. Meanwhile, renewed scrutiny of the 340B drug discount program has systems bracing for further cuts.
    • “What began as isolated state efforts has evolved into a broader movement to rein in hospital prices. Whether these policies ultimately lower costs without undermining hospital finances will likely shape the next chapter of healthcare affordability debates.”
  • ZeroHedge shares different perspectives on the Affordable Care Act plan’s enrollment loss.
    • Obamacare enrollment declined by nearly 3 million in 2026, sparking renewed debate about the affordability of healthcare in America.
    • “National politicians and policy experts disagreed on the reasons for the dip in enrollment, with some saying that it was driven by rising premiums. 
    • “Others said the decline was evidence that program integrity measures taken by the Trump administration were successful in rooting out fraud and waste.” 
  • The American Hospital Association News informs us,
    • “The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices used to treat COVID-19, saying circumstances justifying the authorizations no longer exist. The declaration for drugs and biological products will end June 29, 2027, while the declaration for medical devices will end Dec. 26, 2026. The EUA declarations were issued in 2020 to accelerate access to medical products during the COVID-19 pandemic.” 
  • Per a U.S. Office of Personnel Management news release,
    • “The US Office of Personnel Management (OPM), in partnership with the US Department of War (DOW), today announced the launch of War Force, a DOW-specific recruiting initiative under OPM’s Tech Force program designed to attract exceptional software engineers to support the nation’s most critical national security missions.
    • “Through War Force, OPM will recruit top engineering talent from across the country and connect qualified candidates with high-impact technical roles at the Department of War. The initiative builds on the success of Tech Force by tailoring recruitment to the Department’s unique operational and mission requirements.
    • “America’s national security depends on attracting the best technical talent to some of government’s most important missions,” OPM Director Scott Kupor said. “War Force builds on the momentum of Tech Force by connecting outstanding engineers with opportunities to solve complex challenges alongside the War Department. We’re making it easier for top talent to serve their country through meaningful technical work.” * * *
    • “Applicants must be US citizens and eligible to obtain and maintain a Secret/Top Secret clearance. Applications close July 10, 2026. View the job announcement and apply here.”

No Surprises Act news

  • Beckers ASC News reports,
    • “Some surgical assistants are using arbitration provisions in federal billing law to collect far more than the surgeons they assist, according to The New York Times.
    • “Surgical assistants are typically paid a standard fee equal to about 16% of a surgeon’s reimbursement. But some are now collecting far more than the surgeons they assist by capitalizing on a law meant to protect patients from surprise billing, according to a New York Times report.” 

From the Food and Drug Administration front,

  • BioPharma Dive reports,
    • “The Food and Drug Administration is losing another top drug reviewer in Vijay Kumar, who intends to step down as acting director of the office of gene and cell therapy reviews in the Center for Biologics Evaluation and Research, a spokesperson said Tuesday.
    • “Acting CBER Director Karim Mikhail will serve as the acting director of the Office of Therapeutic Products “to ensure absolute regulatory continuity” while the FDA seeks candidates for the role within and outside the agency, the spokesperson said. Kumar will remain with the FDA, having been elevated to the acting director role from his position as lead physician.
    • “Kumar’s decision comes amid personnel turbulence at the FDA, following the resignation of former Commissioner Marty Makary and CBER Director Vinay Prasad, along with the firing of Tracy Beth Høeg as director of the Center for Drug Evaluation and Research. Multiple top-level positions at the agency are staffed by officials in time-limited acting roles, without a clear indication when they will be filled permanently.”
  • Per an FDA news release,
    • “The U.S. Food and Drug Administration today approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). It represents a novel approach to allogeneic hematopoietic stem cell transplantation in some adult patients with high-risk blood cancers. It addresses an important unmet need in transplantation, where curing the cancer is often only part of the challenge; avoiding chronic GVHD is equally important for long-term outcomes.
    • “Tregzi uses stem cells and immune cells collected from blood of a closely matched donor to help the body fight cancer while reducing the risk of a serious complication called chronic GVHD — a condition that can occur when transplanted donor blood cells attack the patient’s body. Patients receive this treatment after undergoing chemotherapy to prepare their bodies for a bone marrow or stem cell transplant.
    • “For patients with blood cancers who need stem cell transplantation, chronic graft-versus-host disease has long been one of the most feared and difficult-to-prevent complications,” said Karim Mikhail, B.Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER). “Today’s approval offers a genuine new approach that can help reconstitute the immune system while substantially reducing that risk and reflects the promise of what cellular therapy can deliver for patients.”  
  • The Wall Street Journal relates,
    • “U.S. officials are allowing Zyn to market itself as being less harmful than traditional cigarettes, making the product the first nicotine pouch on the market to be granted such a distinction.
    • “The Food and Drug Administration announced that 20 different Zyn nicotine pouches—including flavors ranging from cool mint to cinnamon—can carry language stating that using the pouches instead of smoking cigarettes puts users at a lower risk of mouth cancer, stroke, heart disease, lung cancer, emphysema and chronic bronchitis.
    • “Zyn nicotine pouches, a product of Swedish Match USA which is owned by Philip Morris International PM -1.07%decrease; down pointing triangle, contain no tobacco and are the most popular brand in the U.S. They were granted permission to stay on the market in early 2025, the first pouch to receive the authorization.
    • “Nicotine pouches look similar to small tea bags and are filled with nicotine, salt and can contain other materials like flavorings and wood pulp.” 
  • Beckers Hospital Review tells us,
    • “The New England Journal of Medicine has retracted the clinical trial publication behind Amgen’s rare disease drug Tavneos after two of the study’s authors requested the retraction over undisclosed changes to how patient outcomes were assessed. 
    • “In a June 29 retraction statement, NEJM said the primary endpoint assessments for nine patients were readjudicated after the trial’s database was locked and unblinded, without the two authors’ knowledge, calling the omission “inconsistent with proper research conduct.”
    • “The retraction is the latest setback in a months-long dispute between Amgen and the FDA over Tavneos, a treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis that Amgen acquired through its $3.7 billion purchase of ChemoCentryx in 2022. The FDA first asked Amgen to voluntarily withdraw the drug from the market in January, citing concerns over how ChemoCentryx had re-adjudicated efficacy data for nine of the 331 patients in the pivotal trial. Amgen declined the request on Feb. 3, saying it was not aware of issues with the underlying patient data and that its own review of clinical findings and real-world evidence continued to support the drug’s effectiveness.”
  • Per Cardiovascular Business,
    • “Stryker is recalling its InZone Detachment System due to a potential battery issue. The recall includes a total of nearly 45,000 devices. 
    • “The InZone Detachment System helps interventional radiologists and neurosurgeons perform neurovascular embolization procedures to treat intracranial aneurysms, and neurovascular abnormalities such as arteriovenous malformations and fistulae. The device is also indicated for arterial and venous embolizations in the peripheral vasculature.
    • “The device, compatible with a variety of detachable coils, was designed to detect potentially challenging conditions and adjust as necessary. It includes a detachment button, a series of LED indicators and a cable connection port.”
  • and
    • “Artivion, an Atlanta-based medtech company, has received U.S. Food and Drug Administration (FDA) approval for its AMDS Hybrid Prosthesis.
    • “The AMDS was designed to help clinicians treat DeBakey Type 1 dissections complicated by malperfusion. It works as a complement to hemiarch replacement, preserving the native arch and making reinterventions possible if needed. According to Artivion, it is the first surgical device of its kind.
    • In December 2024, the AMDS received the FDA’s Humanitarian Device Exemption (HDE). This allowed select patients to undergo treatment with the device, but a separate institutional review board (IRB) approval was still required in each instance. Thanks to this full approval, the AMDS is now covered across the board for the treatment of all DeBakey Type 1 dissections with clinical or radiographic malperfusion.”

From the public health and medical / Rx research,

  • The New York Times reports,
    • “Two of the hottest trends in health — longevity medicine and weight loss drugs — are colliding.
    • “A theory that GLP-1 medications like Ozempic or Zepbound might help people live longer has been bandied about by biohackers and aging researchers for several years. Online pharmacies already market compounded versions of the drugs to purportedly extend health span. But so far, academic research into the hypothesis has been scant.”
  • Per a National Institutes of Health news release,
    • “The National Institutes of Health (NIH) has issued the most expansive data release in the history of its All of Us Research Program, making available data from more than 747,000 participants and establishing All of Us as the world’s largest integrated genomic and electronic health record (EHR) database. The latest data release includes more than 535,000 whole genome sequences linked to nearly 482,000 electronic health records, a combination of genomic depth and clinical breadth unmatched by any research program in the world.
    • “There’s a paradox at the heart of precision medicine,” said NIH Director Jay Bhattacharya, M.D., Ph.D. “To tailor treatments to individuals, you actually need very large populations to uncover the patterns that connect genetics, lifestyle, and the environment to health outcomes. That is exactly what All of Us provides: research at unprecedented scale.”
    • The new data issuance represents growth of more than 114,000 participants since the previous data version, bringing the program’s total enrolled-participant count to over 883,000. The dataset now encompasses more than 1.3 billion genetic variants, 553,000 genotyping arrays, 96,000 structural variant records, and 600,000 physical measurements, alongside 747,000 survey responses capturing social circumstances, behaviors, and environments. EHR data grew by 22% in this release, driven by expanded data sources including participant-mediated EHR submissions and health information exchange data.
    • “All of Us reflects the trust of people across the country who chose to contribute to research to benefit everyone,” said All of Us Research Program CEO Josh Denny, M.D. “This release puts a richer dataset into the hands of scientists working on real clinical problems. This is how we advance the health of all Americans.”
  • Health Day relates,
    • “Many young adults may be missing important preventive healthcare screenings, according to a national survey.
    • “The poll of more than 1,000 U.S. adults, commissioned by Ohio State University in Columbus, found only 71% of people ages 18 to 29 have a regular doctor, compared with 97% of adults 65 and older.
    • “Even among young adults who do have a doctor, fewer than half — just 47% — had a checkup in the past year.
    • “The authors say skipping routine visits can mean missing recommended screenings, vaccines and early warning signs of conditions like high blood pressure, high cholesterol and diabetes.
    • Dr. Zachary Bittinger, a family medicine physician at Ohio State University Wexner Medical Center, said having a primary doctor is especially important when you are young.
    • “We look ahead five years, 10 years and 20 years, because that’s ideally how long you see your primary doctor,” he said. “That kind of relationship means that for each stage of life, from college to raising children to retirement, you get the kind of advice that keeps you safe.”
  • MedPage Today informs us,
    • “A large population-based cohort study in Hong Kong demonstrated that acetaminophen (Tylenol) use during pregnancy was unlikely to increase the risk of autism spectrum disorder or attention deficit-hyperactivity disorder (ADHD) in exposed children.
    • “In sibling-matched analyses, prenatal acetaminophen exposure was not associated with autism (adjusted HR 1.00, 95% CI 0.91-1.11) or ADHD (adjusted HR 1.01, 95% CI 0.93-1.08), reported Eric Yuk Fai Wan, PhD, of the University of Hong Kong, and co-authors.
    • “Findings were consistent regardless of when exposure happened, the cumulative acetaminophen dose, or how often the drug was used, the researchers wrote in JAMA Internal Medicine.
  • MedCity News discusses “The Terminology Gap Undermining Cervical Cancer Screening Guidelines.”
    • “While the Pap identifies the cell changes, the HPV test determines the root cause before those changes even happen. Both tests have saved lives. But they are not interchangeable, and treating them as such puts the patient at risk.” 
  • Genetic Engineering and BioTechnology News points out,
    • “Neurodegenerative diseases affect tens of millions of people worldwide. A new study published in Cell Death Discovery titled, “Sustained dysregulation of iron and glutathione homeostasis induces chronoferroptosis, a persistent ferroptotic adaptation in neuronal cells,” points to iron accumulation as a key target in the effort to predict, prevent, and treat neurodegenerative diseases. 
    • “Resilience has become a huge topic of discussion when it comes to Alzheimer’s disease and other neurodegenerative disorders, trying to make the brain more resilient in the face of stressors that contribute to neurodegeneration,” said Pam Maher, PhD, co-corresponding author and a research professor at the Salk Institute. “Our study reveals that cells lose resilience when iron hits a certain level, making neurons more susceptible to stressors that damage or even kill them.”
    • “Found in dark leafy greens, starchy cereals, lean meats, seafood, and other common foods, iron helps red blood cells develop, carries oxygen, makes hormones, and engages in key functions across the immune system and energy production. 
    • “It’s one of the most important minerals in the body,” says co-corresponding author Nawab John Dar, PhD, a postdoctoral researcher in Maher’s lab. “So, it isn’t the iron itself that is a problem with age. It is this accumulation of iron over time that is the problem.” 
  • BioPharma Dive notes “10 clinical trials to watch in the second half of 2026.”
    • “The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.”

From the U.S. healthcare business and artificial intelligence front,

  • Beckers Payer Issues reports,
    • “Some CEOs may come and go. But David Cordani, the outgoing CEO of The Cigna Group, has been with the company for around 35 years, becoming president in 2008 and CEO in 2009.
    • “Mr. Cordani departs his role July 1 but will remain as executive chair of the board. Prior to his Cigna head executive position, Mr. Cordani assumed leadership roles in finance, marketing and operations across the company. Later, he played a broader role in the health insurance landscape, as well, serving as AHIP chair in 2019. 
    • “During his time as Cigna’s CEO, Mr. Cordani gave the company a major makeover, betting big beyond insurance. Those bets appear to have paid off: In 2025, the company brought in about $275 billion in revenue, up from roughly $18 billion when Mr. Cordani began his tenure, according to Cigna. The company now employs more than 70,000 and serves about 185 million customer and patient relationships across its business lines.
    • “Since becoming CEO, one of Mr. Cordani’s boldest moves was the $67 billion acquisition of pharmacy benefit manager Express Scripts in 2018. The deal survived Justice Department scrutiny and ultimately paved the way for Cigna to unify health services under the Evernorth Health Services brand in 2020. In 2025, Evernorth brought in nearly $235 billion in revenue, with more than $132 billion from pharmacy benefit services and $102 billion from specialty and care services.”
  • The American Hospital Association News relates,
    • “The AHA June 30 announced the appointment of Steve Walsh as its next president and chief executive officer. Walsh, who has served as president and CEO of the Massachusetts Health & Hospital Association since 2017, will assume leadership of the nation’s largest hospital and healthcare system membership organization this fall.  
    • “Following a thoughtful national search, the Board unanimously selected Steve Walsh to serve as the next President and Chief Executive Officer of the American Hospital Association,” said Marc L. Boom, M.D., chair of the AHA Board of Trustees and president and CEO of Houston Methodist. “Steve is a proven healthcare leader, innovator and accomplished advocate for healthcare improvement, who understands both the challenges facing hospitals and the opportunities ahead. Throughout his career, he has demonstrated an ability to bring people together, build consensus and advance meaningful solutions on behalf of patients, caregivers and communities.” 
    • Boom also thanked and praised outgoing AHA President and CEO Rick Pollack, noting the “Board’s decision reflects our confidence that Steve is uniquely prepared to build upon the strong foundation established by Rick Pollack while helping the Association strengthen its role as a trusted voice, convener and advocate for health care providers across America.” 
  • Modern Healthcare tells us,
    • Empath units are gaining national attention for improving care for people in crisis while reducing the strain on ERs ill-equipped to treat them.
    • “M Health Fairview Southdale Hospital loses $500,000 annually on its Empath psychiatric unit due to insufficient government reimbursements.
    • “Hospitals are pressing for higher payments for such visits, which are less intensive than inpatient admission but more involved than outpatient therapy.”
  • MedTech Dive informs us
    • “Zimmer Biomet has agreed to pay up to $140 million to acquire Pacira BioSciences’ iovera pain relief device, the companies announced Tuesday.
    • “Zimmer has agreed to pay $70 million upfront and up to $70 million more in revenue-based milestones through 2031. Zimmer will acquire the rights to develop, manufacture and sell iovera as part of the agreement. 
    • “BTIG analyst Ryan Zimmerman wrote in a research note Tuesday that the acquisition complements Zimmer’s existing product portfolio. Iovera has room to expand into new markets and is supported by legislation that went into effect last year to expand access to non-opioid pain treatments.”
  • Per STAT News,
    • “Anthropic, the artificial intelligence firm, on Tuesday announced the availability of Claude Science, an application that optimizes the company’s large language model for use in scientific laboratories and, especially, within the research operations of pharmaceutical companies.
    • “At a launch event here, Anthropic CEO Dario Amodei said that until now, humans have wrestled with the complexity of biology only with their minds. While biology is not as simple or clean as code, he still thinks it can be just as powerful in this domain.
    • “It’s going to be a general purpose technology that helps us to make sense of that complexity, in its full complexity, better.” But, he admitted, “We don’t know for sure if that’s going to work out. But I think we’re seeing signs that we’re seeing the beginnings of it.”
    • “The product is a beachhead in Anthropic’s larger battle for the future of biology. The firm has ambitions so big they would seem caricature-like were it not for its financial means. A month ago Anthropic said it had reached annualized sales of $42 billion — about as much as the drug giant GSK — and that it is valued, based on a $65 billion funding round, at $965 billion, far more than any health care company except Eli Lilly.”

Monday report

Simplicity is a virtue.

From Washington, DC,

  • Per a House of Representatives news release,
    • “Health care providers that deliver high-quality, cost-effective care to American patients will be able to operate more efficiently thanks to bipartisan legislation approved by the U.S. House of Representatives. The Health Care Efficiency Through Flexibility Act (H.R. 5347), introduced by Ways and Means Health Subcommittee Chairman Vern Buchanan (FL-16) and fellow Committee member Representative Jimmy Panetta (CA-19), recognizes the benefits Accountable Care Organizations (ACOs) provide to patients in the way of value-based care, but also that current reporting processes required by the Centers for Medicare & Medicaid Services (CMS) are onerous and costly. As more ACOs deploy sophisticated electronic health records (EHRs) to streamline data reporting to CMS, the legislation provides ACOs with certainty and flexibility to help make the transition to digital quality measure reporting successful.” * * *
    • “Read a fact sheet on the bill here.
    • “The bill passed the Committee with a vote of 43-0.
    • “The bill was approved by the U.S. House of Representatives with unanimous consent.”
  • Bloomberg Government adds,
    • “Senators’ search for affordability wins to boast about on the campaign trail is leading back to capping the cost of insulin at $35 in the private insurance market and for the uninsured.
    • “The proposal is modeled on a similar measure Democrats included in their 2022 tax-and-healthcare law designed to curb costs for the diabetes drug in the federal health insurance program for seniors. 
    • “This time, the private-market insulin cap is being pushed by Sen. Susan Collins (R-Maine), who is facing a tough reelection battle this fall. She said last week that she added two more co-sponsors to her bill. 
    • ‘Fourteen Republican senators are now signed on, including Sens. Dave McCormick(R-Pa.), Tommy Tuberville (R-Ala.), Lisa Murkowski (R-Alaska), Jim Banks (R-Ind.), Chuck Grassley (R-Iowa), and Cindy Hyde-Smith (R-Miss.), as well as 12 Democrats.
    • ‘The measure, which previously earned the support of seven Republicans the last time a version of the idea was considered, could serve as a rare bipartisan triumph for lawmakers in what’s been a divisive Congress. 
    • “Every day we’re gaining momentum,” said Collins of her growing number of supporters on the bill. “There’s a hole here that we want to plug, and that is for people on employer plans and people who are uninsured.”
  • KFF reports,
    • “A new KFF analysis finds that 3.8 million Medicare beneficiaries met the criteria to be eligible for the new Medicare GLP-1 Bridge, based on claims data from 2023.
    • “The temporary 18-month program, launching on July 1 and running through December 2027, will provide coverage of three GLP-1s (Wegovy, Zepbound, and Foundayo) used for weight reduction and weight management to eligible beneficiaries who are enrolled in Medicare Part D.
    • “The total cost to the federal government of the program will depend in part on what share of eligible beneficiaries participate, how quickly they take up coverage, and how many prescriptions each participating beneficiary fills during the 18-month period.” * * *
    • “The clinical criteria for determining a Part D enrollee’s eligibility for Bridge include having a BMI of 35 or more; or having a BMI of 27 or more along with certain comorbid conditions. In addition, eligibility is limited to Part D enrollees who don’t have conditions treated by GLP-1 drugs that are currently covered under Part D, such as type 2 diabetes, and who have not filled a GLP-1 prescription in their Part D plan in 2026.”
  • Healthcare Dive relates,
    • “Enrollment in Affordable Care Act health plans declined by nearly 3 million people this year as policy turbulence continues to roil the exchanges, according to federal data released Friday. 
    • “About 19.2 million people were enrolled in ACA marketplace plans in February, down about 13% from the same time in 2025. 
    • “The Trump administration attributed the decline to efforts to prevent improper and fraudulent enrollment. But more generous financial assistance for ACA plans also expired at the end of last year, pushing more Americans to drop their plans due to rising costs, experts say.” 
  • Per a U.S. Office of Personnel Management news release,
    • “The US Office of Personnel Management (OPM) today finalized a rule strengthening the federal government’s ability to address serious misconduct and ensure federal employees continue to meet high standards of integrity throughout their careers. 
    • “The rule advances President Trump’s efforts to build a high-performing federal workforce that serves the American people with professionalism, integrity, and accountability. By modernizing federal suitability regulations, the rule provides agencies and OPM with additional tools to address serious misconduct, protect public trust in government, and support a more consistent approach to accountability across the federal workforce. 
    • “For too long, the federal government has had stronger tools to prevent someone with serious misconduct from entering public service than to address the same misconduct once that individual is already employed,” OPM Director Scott Kupor said. “This rule closes that gap, strengthens accountability, and helps ensure the federal workforce continues to earn the trust of the American people.” * * *
    • “Read the final rule here.” 
  • Federal News Network adds,
    • “The Office of Personnel Management is giving many employees in its healthcare and insurance division another chance to accept voluntary incentives and leave their jobs, ahead of their busy season.
    • “OPM told employees in its healthcare and insurance (H&I) division on Monday that most of them will have another shot at opting into the deferred resignation program. Employees who apply and are accepted by OPM will go on paid administrative leave for six months before separating from the agency.
    • “Most of OPM’s healthcare and insurance division employees will also be eligible for early retirement. Federal employees are eligible for early retirement if they have 20 years of service at age 50, or 25 years of service at any age. Eligible employees are allowed to voluntarily retire and earn an immediate annuity.
    • “Eligible employees have until 5 p.m. Eastern on July 13 to accept the DRP or Voluntary Early Retirement Authority (VERA) offers. OPM employees approved for the DRP program will go on paid administrative leave starting Aug. 31, 2026, and will officially separate from the agency on March 1, 2027.”
  • Fierce Healthcare tells us,
    • “The Health Resources and Services Administration highlighted on Monday $140 million in newly opened grant funding opportunities focused on rural health priorities like substance use treatment, workforce development and telehealth. 
    • “Applications for the slew of grants opened over the last few weeks and are set to close throughout July. 
    • “HRSA and its administrator Tom Engels, who promoted the funding opportunities during a Monday event at an Iowa critical access hospital, said the programs build on the administration’s priorities of addressing opioid addiction as well as rural healthcare sustainability, the latter of which includes the ongoing $50 billion Rural Health Transformation Program.”
  • and
    • “The Trump administration unveiled new efforts to strengthen oversight of the Trusted Exchange Framework and Common Agreement (TEFCA), including hiring a federal IT contractor to provide audit, review and compliance support.
    • “TEFCA is the government-backed health data-sharing initiative that allows patients, providers and payers to share health records. It was mandated by the 21st Century Cures Act back in 2016 and went live in December 2023.” * * *
    • “Alliance Global Tech Inc., a company specializing in federal IT services including cybersecurity, cloud solutions and data analytics, was awarded a five-year contract to provide TEFCA audit, review and compliance support for HHS, according to a new USASpending.gov listing. USASpending.gov is an official open data source of federal spending information, including information about federal awards such as contracts, grants and loans.
    • “The five-year contract is worth up to $5.62 million, structured as a one-year baseline, around $1.28 million, with annual renewal options through June 2031.”

No Surprises Act news

  • STAT News reports,
    • “For the past 40 years, it’s been illegal in the U.S. for emergency departments to turn away patients because of an inability to pay. But that only applies to hospitals that contract with Medicare. Houston-based Nutex Health, which runs the hospital Behounek visited, has opted not to at most of its hospitals, so it’s not bound by that law. Nutex claims it complies voluntarily, screening every patient to ensure they’re not dying before demanding payment. But some patients say they were never screened. 
    • “In this way, Nutex is able to have the best of both worlds: It charges emergency department prices while avoiding the responsibilities that usually come with being an ER; namely, taking all comers. It’s just one way Nutex has enriched itself and its investors through exploiting loopholes in laws meant to protect patients. In recent years, that’s meant funneling most of its bills through a surprise billing ban’s arbitration process, even though it’s meant to be a last resort. It’s been a gold mine, quadrupling its revenue. 
    • “There is a growing for-profit business model that is exploiting the benefits and higher revenue that comes with providing emergency care without taking on the risks or obligations of being an emergency department,” said Amber Sabbatini, an associate professor of emergency medicine at the University of Washington. Nutex is one of several companies running microhospitals and freestanding emergency departments, although many are run as satellites of traditional hospitals. They tend to open in wealthier areas where people are likely to have insurance.
    • “The federal arbitration process set up under the No Surprises Act has been a stunning success for providers. Not only are they winning in over 80% of cases, they’re securing payments that are three to nine times in-network rates. The program, known as independent dispute resolution, has also been slammed with far more disputes than federal officials had expected. Because of that, it cost at least $5 billion between 2022 and 2024 alone, potentially wiping out the savings Congress expected it to generate. 
    • “For Nutex, this arbitration process has generated eye-popping returns. In less than a year, the company more than tripled its revenue and profit soared nearly twelvefold. The numbers are so dramatic, in fact, that some investors view the money-making strategy as a house of cards. Several are suing Nutex over what they say is an unsustainable reliance on arbitration wins and a precarious alignment with HaloMD, a middleman whose tactics are the subject of multiple lawsuits.”

From the Food and Drug Administration front,

  • The American Hospital Association News reports,
    • “The Food and Drug Administration has identified a Class I recall of North American Rescue first aid kits containing TRUE METRIX Blood Glucose Monitoring Systems by Trividia, which have also been recalled. The FDA said the Trividia recall is due to an issue with an E-5 error code. Trividia has reported 114 serious injuries and one death associated with its recall. The FDA notice said that North American Rescue has not reported any serious injuries or deaths associated with its issue as of March 27.” 
  • Fierce Pharma relates,
    • “The FDA has accepted two Abbreviated New Drug Applications from generics powerhouse Sandoz for its copycat versions of Eli Lilly’s tirzepatide.The applications are for generic versions of Mounjaro and Zepbound, which help treat patients with type 2 diabetes and obesity, respectively. If Sandoz wins the approvals, the company believes it could launch “one of the first generic tirzepatide products” in the U.S., according to a June 29 release.The company noted that it developed its generic tirzepatide in-house.” 
  • and
    • “Viridian Therapeutics has scored FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with Amgen’s blockbuster Tepezza, the only other medicine on the market for the eye-bulging autoimmune condition.
    • “The FDA nod applies to adults with active or chronic TED, making it the first approved therapy in its anti-insulin-like growth Factor 1 receptor (IGF-1R) class to carry labeling that includes data in both active and chronic TED, the company pointed out.
    • “In addition to this advantage, Viridian hopes to count on a convenience edge over Amgen’s IGF-1R Tepezza.”
  • BioPharma Dive tells us,
    • “On Friday, [June 26] Replimune said that the Food and Drug Administration has accepted the resubmission for its cancer drug RP1, with a decision expected by Aug. 2 and an advisory committee set to convene in July to discuss the twice-rejected application. The latest move is another signal of the changing attitude of the FDA, which was accused of moving the goal post or providing conflicting feedback to companies, leading to delayed or rejected applications under the now-exited leaders Marty Makary and Vinay PrasadMultiple other companies that faced hurdles under the prior leadership are now gaining new chances for their applications.
  • MedTech Dive informs us,
    • “Edwards Lifesciences on Friday received Food and Drug Administration clearance for the Ecliptis left atrial appendage exclusion system, an entry in the FDA’s 510(k) database shows.
    • “The implantable clip is intended to close the left atrial appendage, or LAA, a small pouch-like structure in the heart’s left atrium, to prevent blood clots from forming that can lead to stroke.
    • “The Edwards device is positioned to compete directly with AtriCure’s AtriClip platform and Medtronic’s Penditure system, BTIG analyst Marie Thibault told clients in a note Monday. Boston Scientific and Abbott sell LAA occlusion devices that are implanted in minimally invasive procedures.”
  • Per a FDA news release,
    • “Today, the U.S. Food and Drug Administration announced the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American global competitiveness, strengthen domestic drug manufacturing, and improve the resilience of the U.S. drug supply chain.
    • “The FDA launched the PreCheck Pilot Program on February 1, 2026, in response to Executive Order 14293 signed by President Trump in May 2025 and following a public meeting on challenges and opportunities to facilitate domestic manufacturing. The pilot program is intended to support the development of new U.S. pharmaceutical manufacturing facilities by encouraging earlier FDA engagement and providing a more predictable regulatory pathway for companies that plan to manufacture drugs for the U.S. market, helping support greater access to critical medicines for Americans.” * * *
    • “For more information visit the FDA PreCheck Pilot Program webpage.”

From the judicial front,

  • Federal News Network reports,
    • The Supreme Court on Monday dramatically expanded presidential power, upholding President Donald Trump’s firings of the heads of independent federal agencies with one important exception: the Federal Reserve.
    • “The justices allowed Fed governor Lisa Cook to stay in her job while she fights the Republican president’s effort to fire her over allegations of mortgage fraud, which she has denied.
    • ‘But other than at the nation’s central bank, with its role of setting interest rates, the court held that presidents have free rein to fire agency heads at will, despite federal laws that require a cause for such dismissals and a 91-year-old decision that had limited executive authority.
    • “With the six conservative justices in the majority, the nine-member court jettisoned its unanimous [1932] decision in Humphrey’s Executor that had limited when presidents can fire agencies’ board members — in part to try to ensure decision-making free of political influence.
    • “We hold that such protection from removal is contrary to the separation of powers enshrined in the Constitution,” Chief Justice John Roberts wrote for the court.”

From the public health and medical / Rx research front,

  • MedPage Today reports,
    • “Getting a COVID and flu shot on the same day was not associated with an increased risk of adverse events, according to a target trial emulation using electronic health data from the VA.
    • “Compared with influenza vaccination alone, coadministration of COVID and influenza vaccines was not associated with an increased risk for any of the three composite outcomes of serious or life-threatening, clinically significant, or less severe or self-limiting adverse events, reported Ziyad Al-Aly, MD, of Washington University in St. Louis, and colleagues in the Annals of Internal Medicineopens in a new tab or window.
    • “Of the 46 individual adverse events assessed, two less severe or self-limiting adverse events had “nominal statistical significance” with coadministration — a slightly higher risk of syncope (risk ratio [RR] 1.09, 95% CI 1.02-1.17) and a slightly lower risk for tinnitus (RR 0.95, 95% CI 0.92-0.99) — but no risks were statistically significant after correcting for multiple comparisons.
    • “Even in today’s world, where people have been exposed to multiple prior COVID-19 vaccines and their immune systems have been shaped by at least one COVID-19 infection, vaccines have a reassuring record of safety,” Al-Aly told MedPage Today. “We looked at 46 different outcomes — literally leaving no stone unturned — and we came up empty-handed.”
  • and
    • “Lung cancer screening criteria based on the duration of smoking appeared to be a better option for determining individuals at highest risk for lung cancer in an observational study.
    • “Compared with USPSTF recommendations, criteria based on the minimum number of years smoked (20, 30, or 40 years) identified more individuals most expected to benefit from screening.
    • “A threshold of at least 40 years of smoking was also more effective than the USPSTF in excluding people least expected to benefit from screening.”
  • Health Day relates,
    • “Brain imaging could help doctors use magnetic stimulation to better treat depression.
    • “Brain imaging helps find specific targets for stimulation.
    • “People treated using brain imaging had lower symptoms and better response rates.
  • and
    • “Women with preeclampsia have increased risk of developing hypertension and chronic kidney disease (CKD) later in life, according to a study published online May 19 in BJOG: An International Journal of Obstetrics and Gynaecology.” * * *
    • “The most surprising finding was how clearly the amount of protein in the urine during preeclampsia was linked to the risk of later high blood pressure and chronic kidney disease,” Dr. Vestergaard said in a statement. “Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”
  • MedTech Dive informs us,
    • ‘Johnson & Johnson said last week that it has started pivotal development of a Shockwave Medical device for treating calcified carotid arteries.
    • “J&J designed the investigational device, called SkyRunner, to repurpose Shockwave’s intravascular lithotripsy technology for breaking up calcium in the carotid artery.
    • “A physician in Michigan recently treated the first patient in the investigational device exemption clinical program for SkyRunner.”

From the U.S. healthcare business and artificial intelligence front,

  • Fierce Healthcare reports,
    • “As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between payers and manufacturers.
    • “Brian Evanko, president and chief operating officer for the Cigna Group, and Miguel Fernández Alcalde, president of EMD Serono, spoke at a keynote session at AHIP 2026 earlier this month, discussing the delicate balance between promoting innovation and ensuring affordability.
    • “The two companies are longtime partners and most recently worked alongside one another on the cost of fertility treatments. Evernorth operates Freedom Fertility, the largest provider of fertility specialty pharmacy services in the U.S., while EMD Serono is a leader in fertility on the manufacturer side.
    • “Evanko said the partnership deepened last year, when both worked with the Trump administration to drive down the cost of certain fertility treatments. Patients can sign up for Trump Rx and find treatments at a cash-pay price of between $1,000 and $1,500, depending on the number of doses in a course of treatment, he said.”
  • and
    • “AI startup Doctronic is partnering with Simple HealthKit, an at-home health screening platform, to offer consumers end-to-end diagnostic screening integrated with virtual clinical care.” * * *
    • “Simple HealthKit offers at-home screening kits directly to consumers through its website and retail partners and also works with health plans, providers and public health programs.
    • “Through this partnership [with Doctronic], we are initially focused on the conditions where we can deliver the greatest immediate impact across our national health plan and retail partnerships, with plans to expand across our broader portfolio over time. Our vision is to make high-quality healthcare accessible for all,” Simple HealthKit co-founder and CEO Sheena Menezes, Ph.D., told Fierce Healthcare.
    • “Doctronic touts that it’s the first AI system legally authorized to practice medicine in the U.S. The startup offers a free personal AI doctor via chatbot to help navigate symptoms and answer medical questions and can connect users with a licensed physician through a virtual visit. Doctronic, available in all 50 states, is being tested by the state of Utah to refill prescriptions as part of a pilot program.”
  • Beckers Hospital Review relates,
    • “Provider compensation continued to rise in 2025, but a new survey suggests health systems may be nearing the limits of what they can sustainably support.
    • “According to the “AMGA 2026 Medical Group Compensation and Productivity Survey,” overall clinical compensation increased 4.3% in 2025. The survey includes data from 451 medical groups and health systems representing nearly 188,000 providers across more than 190 specialties.
    • ‘The increase comes as reimbursement growth remains largely stagnant, creating a widening gap between provider pay and collections.
    • “Over the past several years, provider compensation has increased, but approximately half of the increases have been supported by ongoing growth in wRVU production,” Fred Horton, president of American Medical Group Association Consulting, said in a June 24 news release shared with Becker’s. “In a marketplace with stagnant reimbursement, this is necessary to afford the increases in total cash compensation, but it is not sustainable. At some point productivity will top out, and providers are already adjusting their FTE and seeking alternative work arrangements in response to increased workloads.”
    • “Primary care compensation increased 3.7% in 2025, while medical specialties saw a 4.3% increase and surgical specialties experienced a 3.2% increase. Compensation for radiology, anesthesiology and pathology providers grew 5.7%, the highest increase among specialty categories tracked by the survey.”
  • Fierce Pharma tells us,
    • “Likely thanks to the Juneteenth federal holiday, prescriptions for both Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo were lower compared with their highest. For the week ended on June 19, Foundayo logged 20,594 total scripts, down from 21,648 the prior week, according to IQVIA data cited by Jefferies. 
    • “For oral Wegovy, the numbers were about 152,000 for the June 19 week, a roughly 9,500 (5.9%) decrease from the prior week. 
    • As Jefferies’ analysts noted, most GLP-1 scripts were down or rather flat in their weekly comparisons. Injectable Wegovy added about 1,000 (0.3%) scripts, landing at 315,000. Mounjaro essentially saw no change, at 804,000.
    • Lilly has previously noted that it takes time to build awareness for Foundayo as a new brand, whereas Novo benefits from familiarity with the Wegovy moniker.” 
  • The Wall Street Journal informs us,
    • Ipsen IPN said it agreed to buy Kartos Therapeutics in a deal valued at up to $1.75 billion that seeks to strengthen the French drugmaker’s pipeline of cancer medicines.
    • “Through the acquisition, Ipsen adds a late-stage drug candidate for myelofibrosis–a rare blood cancer–to expand its portfolio in oncology, it said Monday. Ipsen is paying $450 million upfront to take over Kartos, with additional payments of up to $1.3 billion subject to regulatory and sales targets.
    • “The deal builds on Ipsen’s acquisition of oncology specialist ImCheck Therapeutics for up to 1 billion euros ($1.14 billion) last year after Somatuline, the company’s top-selling medicine, faced generic competition in recent years.
    • “Redwood City, Calif.-based Kartos is a privately held pharmaceutical company that was founded after the licensing from Amgen of an experimental cancer drug. It is developing the drug, navtemadlin, as an add-on therapy to the standard-of-care treatment for patients with myelofibrosis.”
  • BioPharma Dive points out,
    • Royalty management company Zymeworks is buying Theravance Biopharma, announcing Monday a $929 million deal that gives it partial rights to Theravance’s COPD drug Yupelri, along with payouts due from its co-development of Trelegy with GSK and an antibiotic for hospital-acquired infections.
    • Per deal terms, Zymeworks will pay $17 a share, along with a second potential payout should Zymeworks license or sell a drug called ampreloxetine that Theravance has developed for a type of low blood pressure. Zymeworks is partially financing the deal by borrowing $350 million from Omers Life Sciences, which will be paid off with Yupelri’s cash flow.
    • Theravance initiated a strategic review of its business in 2024, which accelerated earlier this year when ampreloxetine missed the primary goal of a Phase 3 trial in nervous-system driven low blood pressure in people with the rare disease multiple system atrophy. In a statement, independent Board Chair Susannah Gray said “this transaction achieves the greatest value for Theravance Biopharma shareholders.”
  • OptumRx, writing in LinkedIn, discusses the “Top 5 ways Optum Rx is putting AI into action.”

Weekend update

Simplicity is a virtue.

From Washington DC,

  • The House of Representatives remains in session through July 1 for floor voting and Committee business. The Senate left Capitol Hill last Thursday and will not return until July 13.
  • MedCity News reports,
    • “A group of Democratic senators introduced a new bill on Thursday that would create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries.
    • “The Medicare Cost Cap Act was introduced by Senator Lisa Blunt Rochester (D-Delaware), Senate Finance Committee Ranking Member Ron Wyden (D-Oregon) and Senate Democratic Leader Chuck Schumer (D-New York).
    • “The bill seeks to “level the playing field” between traditional Medicare and Medicare Advantage, which has annual out-of-pocket spending caps (as do employer-sponsored insurance and coverage bought on the marketplace).” 
  • Healio notes,
    • “It has been nearly a year since the U.S. Preventive Services Task Force released new recommendations, and experts remain concerned about its future.
    • “HHS removed the chair and vice chair of USPSTF last month, which came after three task force meetings were canceled under HHS Secretary Robert F. Kennedy Jr.’s tenure.

From the judicial front,

  • Healthcare Finance reports,
    • “CareFirst of Maryland has filed a federal racketeering lawsuit against two former Maryland insurance brokers, alleging they used fake residences, false identities and an international referral network to enroll out-of-state and overseas clients in CareFirst health plans reserved for Maryland residents.
    • “The complaint, filed June 15 in the U.S. District Court for the District of Maryland, names Avraham Rappaport, a former licensed insurance broker based in Olney, Maryland, and his brother Eliezer Rappaport, a financial advisor and former licensed broker. It also names John Does 1-20 as alleged co-conspirators.
    • “CareFirst described itself in the filing as the victim of a “health insurance fraud conspiracy of breathtaking scale and audacity.” The insurer alleges the brothers coordinated an “international insurance-fraud machine” that allowed people who did not live in Maryland to obtain coverage through CareFirst policies intended for state residents.”

From the public health and medical / Rx research front,

  • NPR lets us know “8 things to know about the gut microbiome and keeping yours healthy.”
  • Health Day reports,
    • “A next-generation blood test could improve early detection of the most dangerous forms of prostate cancer.
    • “The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are truly dangerous,” said first author Thorgerdur Palsdottir, a researcher at the Karolinska Institute in Stockholm. 
    • “Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA [prostate-specific antigen], without increasing the number of unnecessary follow-ups,” she added in a news release.” * * *
    • “Unlike the standard PSA test, which measures a single blood protein, the Stockholm3 test combines multiple protein and genetic markers with factors like age and family history to better assess the risk of aggressive prostate cancer.
    • “The study — published June 23 in the Annals of Internal Medicine — showed that Stockholm3 detected 90% of prostate cancers, compared with 74% for PSA, without subjecting more men to unnecessary testing.”
  • Medscape relates,
    • GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies.
    • One found that GLP-1 RA users had a roughly 30% lower incidence of breast cancer than was seen in matched nonusers. The smaller of the two, which followed more than 80,000 women at high risk for breast cancer, found a more modest 16% reduction.
    • Using GLP-1 drugs to prevent cancer is “an exciting new frontier that will likely revolutionize the field of oncology, but like any new exciting therapy we need [randomized] clinical trials to understand how to optimally” use them, said Neil M. Iyengar, MD, a breast medical oncologist who was not involved in either study.
  • Cardiovascular Business tells us,
    • Transcatheter aortic valve replacement (TAVR) is associated with certain early benefits for women not seen with surgical aortic valve replacement (SAVR), according to a new meta-analysis published in JACC: Advances.[1] These benefits were primarily seen in intermediate- and high-risk patients—and they weren’t seen at all when treating men.
    • “As TAVR expands to younger and lower-risk populations, clarifying sex-specific and time-dependent outcomes is critical for individualized valve selection,” wrote first author Hendrianus Hendrianus, MD, a researcher with Chung-Ang University in South Korea, and colleagues.
    • “The group explored data from nine different randomized controlled trials (RCTs) comparing TAVR and SAVR. Studies were required to include sex-stratified outcomes to be counted as part of this meta-analysis. The nine RCTs included more than 9,500 patients with severe aortic stenosis who were randomized to undergo TAVR or SAVR. Approximately 44% of all patients were women. The primary outcomes for these trials were slightly different from one another, but they all included all-cause mortality as a key component.
    • “After one year, TAVR was linked to a 33% relative reduction in the risk of the trial-defined endpoint for women. This was largely driven by improvements for intermediate- and high-risk patients. This trend was not seen in men.” 

From the U.S. healthcare business and artificial intelligence front,

  • BioPharma Dive reports,
    • “A surge in licensing deals involving drugs from Chinese pharmaceutical firms has triggered alarms in U.S. biotech circles, setting off arguments over what it means for national security and market competition.
    • “Nearly 100 agreements between Chinese and U.S. biotechnology firms have been publicly announced since the start of 2025, according to BioPharma Dive data. Lawmakers on Capitol Hill have signaled intentions to try and disincentivize those investments. Among recent efforts are a push to add the biotechnology sector to the list of industries where investments in China will be scrutinized by U.S. regulators.
    • “The issue featured prominently [last] week at the annual meeting of the Biotechnology Innovation Organization, the industry’s top lobbying group. Multiple panels were geared towards the way licensing deals are affecting the business development landscape and early venture investment. And during a brief meeting with reporters, BIO CEO John Crowley acknowledged the tough spot the U.S. biotech ecosystem is in as well as the pros and cons of Congressional intervention.
    • “Protecting U.S. biotech is a “national security imperative,” and “we need to maintain our lead here,” he said.”  
  • Fierce Healthcare offers a ranked list of the most expensive EHR projects underway in 2026, and relates,
    • Innovaccer and Amazon Web Services (AWS) signed a multi-year strategic collaboration agreement to help health systems and payers deploy agentic AI solutions at scale. 
    • ‘The collaboration aims to bridge the gap between working AI pilots and deployments that meet security, compliance and scale requirements. Under the agreement, Innovaccer will scale agentic AI workloads using AWS services while expanding its go-to-market through the AWS marketplace.
    • “Innovaccer CEO and co-founder Abhinav Shashank said in a statement AI in healthcare, “has a production problem, not an innovation problem.”
    • “The organizations we work with are not short on ambition,” Shashank said. “What they need is the infrastructure to run AI agents reliably, securely, and at the scale their operations demand. AWS gives us exactly that, and what we bring is a decade of healthcare-native context that makes those agents actually work in the environments health systems and payers operate in every day. This agreement is about closing the gap between what AI can do for healthcare and what healthcare is currently getting from it.”
    • The collaboration also includes co-investment in customer success programs, the companies say.”
  • Health Day tells us,
    • “People are becoming more comfortable communicating with their doctor through clinics’ patient portals.
    • “Folks use the portals to ask their doc questions and even to review the results of recent medical tests.
    • “But there are some matters that still require a face-to-face interaction between doctor and patient, a new study says.
    • “In all, 3 of 4 patients want to hear about a cancer diagnosis directly from their doctor, rather than through a portal message or report, researchers reported June 24 in JAMA Network Open.
    • “While most patients in the general population appreciate rapid electronic access to test results, the situation for patients with cancer is much more nuanced,” lead researcher Dr. Sheena Bhalla said in a news release. She’s a medical oncologist at the Harold C. Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center in Dallas.”
  • Per Medical Economics,
    • “People enjoy healthier lives when their physicians work with community partnerships, sharing the goal of improving social and behavioral factors that treat or worsen chronic disease.
    • “Using Community Partnerships to Inform the Prevention Strategy of the Center for Medicare and Medicaid Innovation” is a new consensus study report published this spring by the National Academies of Sciences, Engineering, and Medicine. Its Standing Committee on Primary Care drafted it as a detailed road map for building effective partnerships between physicians’ practices, health care organizations, and community organizations. The committee examined what makes these partnerships work, where they fail, and what the federal government should do to fund and sustain them at scale. Drawing on real-world models from Massachusetts to Alaska, it delivers three concrete recommendations for the Centers for Medicare & Medicaid Services.
    • “This slideshow summarizes the report’s key findings. All data points come from the report, which is available free online.”

Cybersecurity Saturday

From the Project Glasswing front,

  • CNBC reports,
    • “A U.S. official told The Associated Press on Tuesday [June 23] that one of Anthropic’s artificial intelligence models had identified vulnerabilities in highly sensitive and secure U.S. government computer systems during a testing exercise.
    • “The official, who spoke on the condition of anonymity to discuss the matter, said Anthropic had teamed up with U.S. intelligence agencies to conduct tests using the company’s Mythos model. It had identified certain vulnerabilities within hours, but that does not mean the model was able to exploit them within that time, the official said.
    • “The official said the testing was done through an Anthropic initiative called Project Glasswing, which brought together tech giants and other companies in hopes of securing the world’s critical software from “severe” fallout that the Mythos model could pose to public safety, national security and the economy.”
  • NextGov/FCW relates,
    • “OpenAI is offering a limited preview of its new GPT-5.6 model series to select partners, part of an “ongoing engagement with the U.S. government” as Washington and leading artificial intelligence developers try to strike a balance between tech innovation and safety.
    • Three models in the company’s GPT-5.6 series — Sol, Terra and Luna — will initially be available to select partners following conversations and previews with government officials, OpenAI said in its Friday [June 26] announcement
    • “That initially limited rollout follows a request made by the federal government. During the narrow preview period, OpenAI will test model capabilities and coordinate with collaborating partners before making it more broadly available. General access to the models will be available “in the coming weeks,” a similar structure to Anthropic’s Project Glasswing that was set up to test its Mythos Preview model.
    • “OpenAI made it clear that it primarily believes in broad, open access to AI models and that limited previews for government partners are short-term.” * * *
    • “OpenAI’s announcement follows Trump’s signing of an executive order earlier this month that calls for leading AI developers to share model access before market release for safety analyses. Signed following last-minute industry pushback regarding overregulation concerns, the order and OpenAI’s choice to voluntarily share its new model with the government signal the priority the White House is placing on AI safety despite trying to thread the needle between a light-tough regulatory posture and ensuring companies are unencumbered enough to innovate.”
  • The Wall Street Journal informs us,
    • “The Trump administration is allowing Anthropic to reoffer one of its banned AI models to trusted companies and government partners, a key step toward rolling back restrictions that fueled industry concern about ad hoc federal regulation of artificial intelligence.
    • “Anthropic can allow dozens of companies and partners trusted by the government to access Mythos 5, one of the two models that the administration banned for foreign use two weeks ago, Commerce Secretary Howard Lutnick said in a Friday letter to Anthropic Chief Compute Officer Tom Brown, a copy of which was viewed by The Wall Street Journal. 
    • “Fable 5, a general-purpose version of Anthropic’s powerful Mythos model that was also banned, remains restricted, and restrictions on Mythos 5 still apply to entities that aren’t trusted partners.
    • “The olive branch from the administration is the result of two weeks of talks led by Lutnick and Brown to address the government’s security concerns, which were sparked by Amazon researchers who found a way to evade Fable’s safeguards.” * * *
    • “An Anthropic spokesman said the company was working to restore access to Mythos 5 for the partners as soon as possible. “We are pleased to see this progress and continue to work with the government to expand access to Mythos 5 and make Fable 5 available for general use again,” he said.” 

From the cybersecurity policy and law enforcement front,

  • Cybersecurity Dive reports,
    • “President Donald Trump on Monday [June 22] set ambitious deadlines for how quickly federal agencies and government contractors must adopt quantum-resistant encryption algorithms, aiming to prevent U.S. adversaries from using quantum computers to decrypt sensitive data in the coming decades.
    • “The United States must take steps to strengthen cryptographic protections for the Nation’s sensitive data, critical infrastructure, and digital economy,” Trump said in a new executive order.
    • “The directive requires the Office of Management and Budget to issue guidance setting two major deadlines for agencies’ adoption of post-quantum cryptography (PQC) in their high-value assets: Dec. 31, 2030, for key establishment, and Dec. 31, 2031, for digital signatures.”
    • “By accelerating the U.S. Government’s PQC migration timeline, this Order ensures that American cybersecurity keeps pace with emerging technology and recognizes the reality of the accelerating quantum industry,” the White House said in a fact sheet about the new order.”
  • Dark Reading adds,
    • “Organizations will face major challenges — and even greater costs — on the road to becoming quantum-ready over the next five years.” * * *
    • “Jonathan Nguyen-Duy, chief technology officer (CTO) at quantum security vendor Arqit, tells Dark Reading that many organizations underestimate the scale of this challenge, viewing post-quantum migration as a technology upgrade.
    • “Cryptography sits everywhere from applications, networks, cloud environments, and software libraries to connected devices and third-party systems,” he says. “That’s why post-quantum migration is much more than swapping one algorithm for another. Every update needs to be tested and implemented without disrupting the business. It requires long-term funding, cross-functional ownership and a level of persistence that many organizations will find challenging.”
    • “Garfield Jones, SVP of research and strategy at post-quantum cryptography vendor QuSecure, says that many agencies are in the inventorying stage, and some have designated PQC leads. “But substantial work remains on implementation and testing of NIST standardized algorithms within agency environments,” he explains. “Smaller agencies may be able to meet these accelerated deadlines, but larger and federated agencies face a more difficult path as previously unaccounted IT and OT assets continue to surface through manual counting processes.”
  • The American Hospital Association News relates,
    • “Leaders of the Five Eyes cybersecurity agencies, consisting of Australia, Canada, New Zealand, the United Kingdom and the United States, released a joint statement June 22 urging resilience as the evolution of artificial intelligence has been rapidly transforming cyber risk. The alert recommends leaders and organizations to understand and assess risk, readiness and accountability; prioritize foundational cybersecurity practices and controls; empower leaders with authority and resources; and remain engaged as threats and guidance evolve. The agencies recommended additional actions to reduce operational, financial and reputational exposure. Specific tactical recommendations include reducing attack surface, accelerating patching processes, addressing legacy systems, reviewing and strengthening identity and access controls, and preparing for incidents before they happen. 
    • “This important advisory from leaders of the world’s most trusted domestic and international cybersecurity agencies amounts to a clear and stark warning for the private sector,” said John Riggi, AHA national advisor for cybersecurity and risk. “Cyber adversaries are using AI to increase the speed, sophistication and severity of cyberattacks. Within months, not years, the rapid development of frontier AI models will accelerate cyber risk. It is recommended that organizations treat cyber risk as an enterprise risk, use AI to bolster network defenses, and mitigate potential risk to patient care and safety by preparing in-depth cyber resiliency and extended clinical continuity plans. It is especially important for hospitals and health systems to prioritize cyber resiliency for mission-critical and life-critical services.” 
       
  • Homeland Security Today informs us,
    • “The Cybersecurity and Infrastructure Security Agency (CISA) published a guide [on June 24] that helps federal civilian agencies advance their zero trust capabilities and adopt modern architectures supported under the Trusted Internet Connections (TIC) 3.0 Initiative. Part of CISA’s Journey to Zero Trust seriesthis guide helps agencies transition away from the limitations of using TIC 2.0 and capitalize on TIC 3.0 flexibilities to employ Secure Access Service Edge (SASE) solutions. Federal agencies will better understand, plan and mature to zero trust architecture to improve user experience, increase visibility and control, and enable telemetry sharing with CISA services.
    • “Many legacy architectures rely on perimeter-based security models such as TIC 2.0 that routes all traffic through centralized controls. Today’s rapidly evolving threat landscape and organizations’ shift to more distributed business models with cloud capabilities and remote workforces reveal shortcomings in legacy perimeter-based paradigms. Based on CISA’s work with federal agencies, this guide helps technical leaders and enterprise architects implement a SASE solution to replace their existing managed trusted internet protocol services (MTIPS) connectivity. The transformation to SASE solution improves network performance, reduces latency, and increases visibility and control.”
  • Per a General Accounting Office news release,
    • “Cloud computing services allow access to resources like networks, storage, and software. It can cost federal agencies less to use these services than to create their own. But using cloud computing services can pose cybersecurity risks.
    • “We looked at how some agencies protect data in the cloud. Agencies we reviewed varied in implementing key cloud computing security practices. For example, some agencies didn’t fully continuously monitor security controls. Also, some agencies didn’t document how to respond to or recover from cybersecurity incidents.
    • “Our recommendations address these issues and more to ensure cloud services are safe.”
  • Security Week points out,
    • “The National Institute of Standards and Technology (NIST) announced Wednesday that it’s seeking public feedback on updated Internet of Things (IoT) security guidelines.
    • “Updated to reflect current security needs, the guidance provides general considerations on the impact of IoT products on risk assessments and aims to establish cybersecurity requirements to support security controls.
    • “The initial public draft (IPD) of SP 800-213 Revision 1, titled ‘IoT Product Cybersecurity Guidelines for the Federal Government: Establishing IoT Product Cybersecurity Requirements’, is available for download on NIST’s website (PDF), with the public comment period ending August 24.
    • “As organizations increasingly rely on IoT products, they need to understand that these products are system elements and must be taken into account in the risk management process, NIST argues.
    • “The updated guidelines build on SP 800-213A, which provides a catalog of IoT product cybersecurity capabilities and non-technical capabilities for both manufacturers and consumers.”
  • Cybersecurity Dive notes,
    • “Microsoft on Wednesday announced a coordinated operation with Europol and other international partners to disrupt Amadey and StealC — tools used as infostealers to conduct ransomware, financial fraud and other digital crimes. 
    • “Amadey is a specialized tool used by cybercriminals to infect computers, while StealC is used to steal passwords and other sensitive data after the computers are infected. The tools are used widely around the globe, with Microsoft finding more than 140,000 computers worldwide infected with the tools during the first two weeks of May. 
    • “Microsoft identified more than 200 malicious Amadey and StealC command-and-control domains and IPs and shut them down using a combination of court-ordered actions, domain seizures and related actions. 
    • “In a filing with the U.S. District Court in Miami, Microsoft accused a series of unnamed defendants of operating a malware-as-a-service enterprise. Microsoft asked the court to disable and transfer control of related internet domains to the company. 
    • “Microsoft, in a blog post Wednesday, said investigators used AI to help analyze how Amadey and StealC were being used in the infostealing operation.” 

From the cybersecurity breaches and vulnerabilities front,

  • HealthExec reports,
    • “Last week, HealthExec reported on a data breach at a healthcare AI company that resulted in personal data from its hospital and payer clients being exposed to hackers. This week, a filing with the federal government provided details on how many patients were impacted. 
    • “According to the U.S. Department of Health and Human Services’ (HHS) Office of Civil Rights healthcare data breach tracker, the number of individuals impacted by the hack on Xsolis was determined to be 1,396,519.
    • “Stolen data was determined to include protected health information, including details on medical treatments that patients received. Names, dates of birth, contacts, Social Security numbers and health insurance information were also compromised. 
    • “Xsolis, a company that uses artificial intelligence to improve patient care utilization, posted a notice earlier this month that contained many of the details of the data security incident, said to have stemmed from a “targeted phishing attack” that resulted in an unauthorized third party accessing its network.” 
  • Cybersecurity Dive relates,
    • “Klue, a provider of a market intelligence platform, is investigating a supply chain attack that led to the mass exfiltration of Salesforce customer relationship management data belonging to hundreds of customers, including several prominent cybersecurity firms. 
    • “A threat actor used a compromised Klue Battlecards app to gain access to OAuth tokens for connecting Klue with third-party integrations, including Salesforce, according to information from Klue and security researchers at Reliaquest, which warned about the attack in a recent blog post. 
    • “Salesforce, which disabled connections through the Klue Battlecards appuntil further notice, said there is no indication of a vulnerability within its own platform. 
    • “A threat actor tracked as Icarus posted stolen data from several victims on its website, according to a Monday [June 22] blog post from Huntress. Itself a victim of the attack, Huntress said none of its internal systems were impacted.
    • “The threat group has begun reaching out to companies whose customer data was compromised in the attack, said Charles Carmakal, CTO at Mandiant Consulting.” 
  • Bleeping Computer tells us,
    • “The FBI and CISA are warning that a phishing campaign targeting Signal users tied to Russian intelligence services has evolved to steal Signal Backup Recovery Keys, allowing attackers to access victims’ historical messages.
    • “The updated public service announcement is an update to a March 2026 advisory that warned the threat actors were targeting users of commercial messaging applications, particularly Signal, through phishing campaigns designed to hijack accounts rather than break end-to-end encryption.
    • “RIS cyber threat actors continue to masquerade as automated CMA support accounts in updated phishing messages but have evolved their tactics to attempt to elicit victims’ Backup Recovery Keys,” warns an FBI PSA published today [June 26].
  • CISA added six known exploited vulnerabilities (KVEs) to its catalog this week.
    • June 23, 2026
      • CVE-2025-67038 Lantronix EDS5000 Code Injection Vulnerability
      • CVE-2026-34908 Ubiquiti UniFi OS Improper Access Control Vulnerability
      • CVE-2026-34909 Ubiquiti UniFi OS Path Traversal Vulnerability
      • CVE-2026-34910 Ubiquiti UniFi OS Improper Input Validation Vulnerability
        • The Hacker News discusses these KVEs all of which required patching within three days.
    • June 25, 2026
      • CVE-2026-12569 PTC Windchill and FlexPLM Improper Input Validation Vulnerability
      • CVE-2026-20230 Cisco Unified Communications Manager Server-Side Request Forgery (SSRF) Vulnerability
        • Bleeping Computer discusses these KVEs. CISA set the same June 28 deadline for federal agencies to patch both KVEs.
  • Cyberscoop adds,
    • “An attacker exploited a previously unknown and unpatched Cisco vulnerability earlier this year to infiltrate a communications service provider and gain the highest level of access possible, Mandiant said Wednesday [June 24].
    • “Cisco has since patched the flaw, one of seven actively exploited zero-day vulnerabilities this year in its SD-WAN (software-defined wide area network) software used to manage internet traffic within organizations, typically those that are widely distributed, such as banks with numerous branches.
    • “But Google-owned cybersecurity firm Mandiant said the attacker (or attackers) could have used its root-level access to obtain broad and undetected visibility into the internal traffic throughout the provider’s entire corporate network. In a caveat, Mandiant also said it could not fully assess how far the compromise actually went because of how cleverly the perpetrators hid their activity.
    • “The attack illustrated hackers’ ongoing targeting of edge devices, Mandiant said. Attacks on such devices have been very common and involved in some of the most consequential breaches in recent years, prompting the Cybersecurity and Infrastructure Agency to direct federal agencies to give them special attention this year.
  • Cyberscoop observes,
    • “When CISA issues an emergency directive, the message to every federal agency and every security team paying attention is to patch now. For CVE-2026-50751, a CVSS 9.3 authentication bypass in Check Point Remote Access VPN, that directive landed on June 21. despite exploitation beginning in early May. That, six-week active intrusion gap is not a footnote. It is the entire story.
    • “The flaw itself is straightforward in the worst possible way. A logic error in the certificate-validation process, triggered when the deprecated IKEv1 key-exchange protocol is enabled, allows a remote attacker to establish a fully authenticated VPN session without a valid password. No phishing. No credential theft. No lateral movement required to reach the perimeter. The attacker walks through the front door, and the door logs it as a legitimate entry.
    • “By the time Check Point disclosed the vulnerability on June 8, a Qilin ransomware. affiliate had already used it to compromise a few dozen organizations worldwide. The post-access playbook was efficient, including Rclone for data exfiltration, the Tox protocol for command-and-control communication routed through disposable VPS infrastructure. Quiet, fast, and designed to complete the job before detection had a chance to matter.” * * *
    • “CISA will issue another emergency directive. There will be another authentication bypass, another perimeter device turned attack vector, another financially motivated threat actor with a head start measured in weeks. The patch-and-detect cycle will play out again, and organizations that had their exposure managed entirely at the perimeter will find themselves in the same position.
    • “The lesson here is not that Check Point failed or that VPNs are over. It is that any architecture where a single authentication bypass gives an attacker operating authority over the entire environment has a structural problem that no patch resolves. Closing the door is necessary. Making sure the ransomware cannot detonate even after the attacker is inside is the part the industry still has not solved at scale.
    • “That is the conversation the CISA directive should be starting, and mostly is not.”
  • Security Week points out,
    • “Researchers at Wiz have disclosed a high-severity vulnerability in the Amazon Q Developer extension for Visual Studio Code that could allow attackers to steal developers’ cloud credentials by luring them into opening a booby-trapped code repository.
    • “Amazon Q Developer is an AI-powered coding assistant that offers developers features such as code suggestions, automated refactoring, and access to external tools and services via integrations with local processes.
    • “AWS was notified about the issue on April 20 and a patch was released on May 12. The cloud giant published a security advisory this week.
    • “The root cause of the vulnerability was that the extension would automatically act on configuration files embedded in a workspace without first asking the user for permission.

From the ransomware front,

  • Cybersecurity Dive reports,
    • “The number of ransomware attacks that hackers claimed on dark-web leak sites rose by nearly one-fifth in 2025, to 6,883, while the total number of leak sites increased by roughly one-third, to 115, the security firm Bitsight said in its annual “State of the Underground” report.
    • “Ten groups — five of them associated with Russia — were responsible for roughly 58% of attacks, according to the report, suggesting a remarkable concentration of activity.
    • “Roughly 60% of ransomware victims were in the U.S., with the manufacturing sector topping the list.”
  • Dark Reading adds,
    • “A specter is haunting Europe — the specter of ransomware.
    • “After a global lull in 2024 and 2025, the ransomware-as-a-service (RaaS) ecosystem appears to be back to form, at least in Europe. Researchers from Black Kite tracked 684 ransomware attacks across the continent through the first four months of 2026. That’s 55% more than the 441 recorded in the first four months of 2025, even more than the 643 recorded through the first half of 2025.
    • “Globally, the US absorbs almost half of all ransomware victims. Canada and the UK have traded second place. Europe was a step behind. Now that’s shifting,” Ferhat Dikbiyik, chief research and intelligence officer at Black Kite, tells Dark Reading. He believes that at least a couple of factors are at play. 
    • “First, an oversaturation of ransomware activity in the US is leading some to seek opportunities elsewhere. And “second, and this is my read: [Attackers’] own artificial intelligence (AI)-assisted target research is starting to point them at Europe,” he says. “The stealer logs are there. The unpatched vulnerabilities are there. The money is there. Smaller countries may run weaker defenses, but the big economies offer the full package: wealth and exposure together. The question isn’t why ransomware groups target the major EU powers; it’s why would you not?”
  • HelpNetSecurity tells us,
    • “A relatively new backdoor called Mistic has been deployed in multiple attacks since April 2026 targeting organizations in the insurance, education, IT, and professional services sectors, according to Symantec.
    • “The malware appears to be associated with Woodgnat, also known as KongTuke, a financially motivated initial access broker (IAB) active since at least May 2024 that has been connected to ransomware operations including QilinInterlock, Rhysida, Akira8Base, and Black Basta.
    • “Woodgnat reportedly functions primarily as an IAB. Its goal is not to deliver the final payload, but to establish highly durable remote access within an enterprise and sell this high-level access to ransomware affiliates and other attackers for a fee,” the researchers said.”
  • CSO Online shares an “Anatomy of a retail ransomware attack: Tabletop simulates modern mayhem methods.”

From the cybersecurity business and defenses front,

  • Cybersecurity Dive reports
    • “A coalition of technology companies, including Anthropic, AWS, IBM and Microsoft, announced a joint effort to find, disclose and remediate security flaws in open-source software. 
    • “The group, called Akrites, will establish a shared security incident response team as well as a coordinated vulnerability disclosure process.
    • “The founding members, led by the Linux Foundation, will commit extensive resources to the effort, including funding, engineers and cybersecurity expertise. 
    • “Officials said the plan was mainly driven by the emergence of frontier AI models that radically accelerated the ability to discover vulnerabilities in critical software applications. In recent months, malicious actors have demonstrated the ability to weaponize AI for use in sophisticated attacks.” 
  • and
    • “AWS launched agentic tools AWS Continuum, which flags and helps remediate security risks, and AWS Context, a search layer that uses a company’s data to make better informed agents, at its AWS Summit in New York City on June 17.
    • “The company rolled out the tools as the rise in AI agents is rapidly changing the way enterprises operate, reshaping the cybersecurity landscape and necessitating tools that connect siloed data.
    • “AWS rolled out new capabilities for AI tools Kiro, AWS DevOps Agent, AWS Transform for modernization and Amazon Bedrock AgentCore to build and deploy agents. It also updated Amazon Quick, an agentic assistant-modeled AI application, which was released as Quick Suite last year.”
  • Dark Reading adds,
    • “In 2025, nearly 3 in 10 security professionals thought that fully autonomous AI systems could satisfy their companies’ security-testing needs. But after a year of testing and experimentation, that optimism has largely gone away.
    • “Instead, chief information security officers (CISOs) and other security practitioners have more realistic expectations of the AI-based systems, which often have significant blind spots, are prone to false positives, and can blow through AI budgets, according to a June 25 report released by Cobalt, a penetration-testing-as-a-service firm. The number of organizations willing to rely on AI-powered penetration testing for their security needs fell to 9% in 2026, down from 29% a year earlier. The vast majority of companies preferred a hybrid, human-in-the-loop approach or relegating only non-critical tasks to automation.
    • “Security practitioners are experimenting to find the sweet spot of what can be automated reliably and responsibly, says Gunter Ollmann, chief technology officer for Cobalt.”
  • HIPAA Journal informs us,
    • “Cybersecurity risk is growing, and healthcare organizations are struggling to defend a rapidly increasing attack surface. AI tools are being implemented without the secure infrastructure to support them. Most healthcare practices have meaningful gaps in cyberattack recovery readiness, face ongoing and regular third-party vendor disruptions, and there is growing concern that a cyberattack will result in a patient fatality. The current state of cybersecurity in healthcare is far from rosy.
    • “These were some of the findings from the 2026 Healthcare IT Landscape Report from Omega Systems, a leading provider of managed IT and security services to the healthcare and financial services industries. The report is based on a survey of 200 healthcare business leaders in the United States, including CEOs, CISOs, CIOs, CFOs, and COOs, at healthcare organizations with between 50 and 600 employees. The healthcare organizations represented in the report include medical practices, clinics, ambulatory care centers, specialty services, and long-term care facilities.”
  • Tech Target offers “A CISO’s guide to infostealers: Prevention and detection.”
    • “Infostealers aren’t new. But what is new is that almost anyone — regardless of skill — can now deploy the malware. Update incident response plans to safeguard your operations.”
  • Security Week notes,
    • “AI agents go beyond answering questions. They can autonomously browse websites, read emails, search company files, query software tools, and more. AI models producing incorrect answers is hardly a threat, until agents encounter information that’s maliciously designed to influence what it sees, believes, remembers, or executes.
    • “An agent leverages webpages, document stores, wikis, images, emails, or tools to produce intended outputs. But what happens when these sources mask malicious instructions? These trap AI agents into making a wrong interpretation or taking unintended action. Scientists from Google DeepMind categorized these “traps” into six categories, including content injection, semantic manipulation, cognitive state, behavioral control, systemic, and human-in-the-loop traps. The last two are more theoretical and expected to become more relevant as AI agent use grows. It helps to understand these traps to determine the necessary mitigations.”
  • Per Cybersecurity Dive,
    • “As cyber risk evolves, the insurance industry tightens guardrails.”
    • “C-suite executives are concerned about resilience, but claims are increasingly tied to strict underwriting standards.”
  • Here is a link to Dark Reading’s CISO Corner.

Friday report

Simplicity is a virtue.

  • OPM Director Scott Kupor added a second Secrets of OPM blog post about the FEHB and PSHB programs today.
    • “One of OPM’s cultural values is to “ask why.” Why do we do things the way we do them? Why does a process exist? Why do we collect one piece of data and not another? Why are we still relying on a framework developed for a bygone era?
    • “Today, we are asking “why” in the context of one of our most important responsibilities: helping ensure that federal employees, retirees, postal workers, and their families have access to high-quality, affordable health benefits. To that end, we have updated our Guiding Principles for Federal Employees Health Benefits and Postal Service Health Benefits carriers.”
      • In the FEHBlog’s opinion, what’s missing from the guiding principles is any mention of deregulating the FEHB and PSHB programs. Deregulation would be the straightest path to restoring competition and thereby lowering premiums. See motto above.
  • OPM also proposed a new workforce rule today which will appear in Monday’s Federal Register.
    • “The Office of Personnel Management (OPM) proposes to amend its regulations to more fully address the appropriate uses of administrative leave, including use in connection with deferred resignation programs and other workforce realignment initiatives, and for other purposes. OPM is also proposing to amend its regulation on resignations to clarify when an agency may accept or deny an employee’s request to withdraw a resignation in the context of a deferred resignation program.”
    • The public comment deadline should be July 29, 2026.
  • Modern Healthcare reports,
    • “President Donald Trump intends to nominate Medicare Director Chris Klomp to be deputy secretary of the Health and Human Services Department.
    • “The pending nomination, which Trump announced on his Truth Social platform Thursday, would further elevate the former healthcare and investment executive within the Trump administration.
    • “Klomp has been director of the Center for Medicare and deputy administrator of the Centers for Medicare and Medicaid Services since April 2025 and senior adviser to HHS Secretary Robert F. Kennedy Jr. since February.
    • “Prior to his government service, Klomp was CEO and chair of the health information technology company Collective Medical from 2014 to 2020, when it was acquired by PointClickCare. He previously held numerous positions at the consulting and investment firm Bain & Co.”
  • The American Hospital Association News tells us,
    • “The Department of Health and Human Services June 26 announced new efforts to improve the Trusted Exchange Framework and Common Agreement. TEFCA is a common set of rules required by the 21st Century Cures Act of 2016 that securely and more easily exchanges healthcare information between networks and providers. HHS said the Office of the National Coordinator for Health Information Technology awarded a new contract to improve oversight of the network and verify that participating organizations are following TEFCA requirements. ONC is also conducting additional reviews of Qualified Health Information Networks and their participants to help ensure compliance. HHS said that the number of health records exchanged through TEFCA has grown from 10 million to more than 1 billion in less than one year.”
  • STAT News adds,
    • “A new charter for the panel that advises the Centers for Disease Control and Prevention on vaccine use substantially refocuses the responsibilities of the committee, downplaying its role in recommending the use of new vaccines and giving it responsibility to assess alternatives for disease prevention.
    • “Whereas previous iterations of the committee’s charter stressed the importance of vaccine research-relevant experience in the selection of its members, the new version, posted to the CDC’s website on Thursday, merely stipulates that the panel as a whole should “represent a balanced range of scientific, clinical, and public health expertise relevant to the Committee’s mission” — a broad umbrella under which people with little experience in vaccines or vaccination policy might conceivably fit.” * * *
    • “The new charter is dated May 14. Several news outlets have reported having seen copies of it in the weeks since. But it’s not clear why it has only been posted now, and the Department of Health and Human Services, which oversees the CDC, has not answered previous questions about why it had not been posted.”
  • Healthcare Dive relates,
    • “The HHS provided an update Thursday on its plans to help speed the adoption of artificial intelligence in clinical care, part of a bid to improve Americans’ health and bring down healthcare costs.
    • “During a webinar, department leaders laid out takeaways from a request for information released late last year asking the sector how the HHS could use its regulatory, research and reimbursement powers to accelerate the use of AI in healthcare. 
    • “The industry wants coordination across HHS agencies, support in AI implementation and governance, and assistance in determining what makes a good AI tool, Arman Sharma, the HHS’ deputy chief AI officer, said. “We believe that starting with these three things and acting on constant engagement from this community is what’s needed to establish trust,” he said. “And trust in this technology is the only thing that will lead to responsible, but also effective, adoption.”
  • The U.S. Census Bureau notes,
    • “The nation’s fertility rate has dropped nearly every year since 2007, but this national decline masks substantial geographic variation.
    • “Fertility rates differ widely across U.S. counties, and even within individual states there are often both high and low fertility counties.
    • “By combining population estimates data released today on the age characteristics of U.S. counties with birth data released in March, we calculated the general fertility rate (GFR) for every county in the nation.” * * *
    • “There are clusters of high GFR counties in many, but not all, states.
    • “For example, there are high GFR counties in southeastern North Carolina that extend into South Carolina, and in southern Georgia that extend into northern Florida.
    • “Moving westward, many states have at least one cluster of counties with high GFRs.
    • “Notably, there are only a few states that do not have any counties with a GFR above 60, including the entirety of New England: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont.”

From the Food and Drug Administration front,

  • Genetic Engineering and BioTechnology News reports,
    • “The U.S. Food and Drug Administration (FDA) is in the middle of a cultural and operational shift that goes beyond leadership changes. U.S.–China biotechnology competition is driving discussions around regulatory reform in the U.S. where traditional paradigms are being reviewed and reconsidered, particularly for rare diseases. And patient perspectives need to be a more integral part of the drug development continuum.  
    • “Those were some of the major themes that emerged from a town hall that took place at this year’s Biotechnology Innovation Organization (BIO) meeting in San Diego, which featured members of the current FDA leadership team. 
    • “John Crowley, BIO president and CEO, moderated the discussion with the acting directors of Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) and the acting chief of staff at the FDA. During the hour-long conversation in a room packed to the hilt with BIO attendees, they spoke about the agency’s current priorities and its plans to increase its headcount, among other initiatives. 
    • “Much of the discussion centered on ongoing plans to stabilize the agency’s workforce following the massive reduction in staffing implemented by the Department of Government Efficiency (DOGE) as well as departures of several leaders in rapid succession. The panelists acknowledged the disruptions to operations, the loss of institutional knowledge, and the past unpredictability at the agency, but did not dwell on it.  
    • “The consensus seems to be that stabilizing the agency’s workforce is an important prerequisite for successfully launching several planned initiatives. In fact, Michael Davis, MD, PhD, acting director of CDER, noted that this has been one of his top priorities. His initial efforts were aimed at “fortifying the center and specifically the workforce” as well as finding ways to retain staff retention and boost recruitment.”  
  • MedTech Dive relates
    • “Aidoc has received the Food and Drug Administration’s breakthrough device designation for an artificial intelligence feature designed to read chest X-rays and generate draft report text, the company said Thursday.
    • “The system, called First Read, is expected to generate preliminary reports on more than 100 pre-specified findings, a spokesperson for Aidoc wrote in an email. A radiologist still must sign every report made by First Read. Aidoc declined to provide the full list of findings as the product is not yet on the market. 
    • “Aidoc CEO Elad Walach said in a statement the feature is intended to help reduce the time radiologists spend on reporting and interpretation.”
  • Radiology Business adds,
    • “The U.S. Food and Drug Administration has cleared a new artificial intelligence-enabled tool designed to assist with the segmentation of brain tumors. 
    • “Denmark-based Cercare Medical has received 510(k) clearance for its Oncology Virtual Expert, an AI-powered brain tumor segmentation tool that can streamline and standardize neuro-oncology imaging workflows. It enables fast, consistent and semi-automated tumor delineation directly from routine MRI studies. The clearance marks a key milestone in the company’s expansion into the North American market. 
    • “The module generates automated tumor segmentation maps from standard MRI data. This reduces reliance on manual contouring, which can be a cumbersome and time-intensive process that is vulnerable to inter-reader variability. The on-premise system can be integrated directly into existing PACS and workflows. It was designed this way so that it can operate within hospital IT constraints, such as strict HIPAA and data governance requirements that can inhibit cloud-based AI adoption in some networks.” 
  • and
    • “The U.S. Food and Drug Administration (FDA) updated its list of cleared artificial intelligence (AI) algorithms, and radiology still maintains its vast lead over the rest of medicine.
    • “The agency’s June 16 update showed 68 new radiology algorithms were cleared just in the first three months of 2026. There are now a total of 1,524 FDA-cleared AI algorithms as of March 30, 2026, and 1,163 of them are for radiology, which now accounts for 76.31% of all FDA-cleared AI. The actual total for medical imaging AI listed under other specialties like orthopedics, cardiology and neurology brings the total closer to 80%.
    • “The FDA has seen an increasing number of AI approvals for the past several years, now clearing about 30 a month. In 2024, the  FDA was clearing an average of 21 per month.”
  • Cardiology Business informs us,
    • “Medline, the Illinois-based medical supplier, is recalling thousands of procedure kits used by cardiac surgeons due to quality issues identified during a U.S. Food and Drug Administration (FDA) inspection. The recall includes more than 6,500 cardiovascular procedure kits primarily used during open-heart surgeries, and more than 500 general surgery trays.
    • “All convenience kits contain Lidocaine Hydrochloride Injection, USP and/or Bupivacaine Hydrochloride in Dextrose Injection, USP. Quality issues with these anesthetics are what prompted the recall.” * * *
    • “Click here for more information from the FDA.” 

From the judicial front,

  • KFF reports,
    • “A major Medicare Advantage company has paid the government more than $342 million to help settle allegations that it overcharged the federal healthcare program for years.
    • “Elevance Health, which covers about 2 million people on Medicare, sent the money to the Centers for Medicare & Medicaid Services via wire transfer on May 27, court records show. Government lawyers disclosed the payment in a June 22 court filing.
    • “In an email to CMS staff, Elevance described the money as a “remittance of the total overpayment amount” estimated by government audits, court records show. Company spokesperson Leslie Porras told KFF Health News in a statement that Elevance Health “continues to engage in constructive dialogue” with CMS. “We remain optimistic that a resolution can be reached and value our longstanding relationship with CMS,” she said.
    • “The payment was made in response to a CMS enforcement action in February, in which the agency threatened to halt enrollments in Elevance Medicare Advantage plans unless the company corrected what CMS called “substantial and persistent noncompliance” with federal regulations that require health plans to submit accurate billing data and return any overpayments when they are discovered.”
  • HR Dive relates,
    • “The U.S. Equal Employment Opportunity Commission sued automotive manufacturer Dana Sealing Manufacturing, alleging the company illegally acquired genetic information from its employees, and issued a warning to other employers as well.
    • “Between 2022 and 2024, the Kentucky-based employer allegedly required applicants to state whether their parents, grandparents or siblings ever had certain listed medical conditions, in violation of Title II of the Genetic Information Nondiscrimination Act of 2008, the complaint claimed.
    • “The Genetic Information Nondiscrimination Act prevents employers from requesting family medical history information from employees and applicants, except in narrow circumstances, none of which applied here,” Kenneth Bird, regional attorney for the EEOC’s Indianapolis District, said in a statement Wednesday. “The EEOC will continue to enforce GINA and other federal anti-discrimination laws.”

From the public health and medical / Rx research front,

  • The Centers for Disease Control and Prevention announced today,
    • “As of June 26, 2026, the amount of acute respiratory illness causing people to seek health care is very low.
    • “RSV activity is low in most areas of the country. Emergency department visits and hospitalizations for RSV are low but remain highest among infants and children younger than 4 years old.
    • “COVID-19 activity is low in most areas of the country.
    • “Seasonal influenza activity is low.
    • “Parainfluenza (PIV), a respiratory virus that can cause illnesses such as croup, is elevated nationally. Human metapneumovirus (HMPV) and rhinovirus/enterovirus (RV/EV), which often cause cold-like respiratory illness, are also elevated nationally but declining. Whooping cough is still circulating.”
  • The University of Minnesota’s CIDRAP reports,
    • “After confirming 31 new measles cases last week, the Centers for Disease Control and Prevention (CDC) today added 30 new infections to the US total, which has now climbed to 2,134 confirmed cases. The numbers move the needle closer to the 2025 total of 2,288 cases.
    • “All but 12 of this year’s cases were locally acquired, with the rest related to travel outside the country. Of the total, 21% of infections are in children age 5 and under, and 72% involve kids and young adults to age 19. Six percent of patients have been hospitalized, compared with 11% in 2025. Among all measles patients, 93% are unvaccinated or have unknown vaccine status. 
    • “No measles deaths have been reported this year, compared with three in 2025.”
  • and
    • “In January 2026, the Health Resources and Services Administration announced that women could choose self-testing for the human papillomavirus (HPV) instead of having a doctor conduct a Pap or cervical cancer test. Experts hoped that this would increase screening for the virus, which is responsible for 90% of cervical cancer. 
    • “A study published today in JAMA Network Open looked at which patients follow through with home testing. While some participated, more outreach needs to be done to include diverse communities, say the authors, from The Permanente Medical Group and Kaiser Permanente Northern California.   
    • “The findings suggest that a substantial proportion of eligible patients will elect home-based screening, but efforts are needed to support participation across demographic groups,” the authors wrote.” * * *
    • “While one in five people asked for a self-test, only one in 10 people returned it. The researchers suspect patients’ history influences their willingness to use a home test. 
    • “Higher uptake observed among older patients may reflect experience with cancer screenings, concern regarding cancer, or discomfort with pelvic examinations,” the authors wrote.” 
  • Beckers Clinical Leadership tells us,
    • “The Trump administration is asking Congress for $1.4 billion to respond to the Ebola outbreak in the Democratic Republic of Congo, Politico reported June 25.”
  • The American Hospital Association News relates.
    • “Emergency department visits for suspected suicide attempts from 2021-2025 were highest among adolescents age 12-17 at 24.8%, according to a report released June 25 by the Centers for Disease Control and Prevention. That age group also had the highest proportion of ED visits for suspected suicide attempts at 82.2 per 10,000 visits. Overall, 60.3% of ED visits for suspected suicide attempts were by women, while men consisted of 39.5% of such visits. The proportion of total ED visits decreased from 2021-2025, with adolescents age 12-17 and adolescent females having the largest decreases. Visit proportions increased among adults older than 26.”
  • Health Day adds,
    • “Poison control calls linked to GLP-1 drugs have risen sharply.
    • “Semaglutide is named in most reported cases.
    • “Most incidents are due to accidental dosing errors.”
  • and
    • “Women on the pill appear to have healthier brains as they grow older, a new study says.
    • “Taking hormone-based birth control as a younger woman appears to protect the brain, maintaining the size of regions vital to memory, cognition and information, researchers report in the July 1 issue of the journal NeuroImage.
    • “Women’s brains also benefited if they took birth control pills during their reproductive years, and then hormone therapy when they entered menopause, results show.
    • “It’s showing a protective effect — using estrogen-based hormone therapies was beneficial for the brain in older women,” co-lead author Amber Watts, a professor of psychology at the University of Kansas, said in a news release.”
  • NBC News lets us know,
    • “People are more worried about severe muscular problems when taking statins than they should be: Such side effects are exceedingly rare, research published Thursday in the journal The Lancet Digital Health reaffirms.” * * *
    • “The new study, which used medical record data from nearly 6 million adults in the United Kingdom, found that only about 0.04% of people had a 10-year risk of statin-related serious muscle disorders above 10%.
    • “That’s even lower than previous figures, including from an American Heart Association report, which put the rate of myopathy at less than 1% and the rate of rhabdomyolysis at less than 0.1%.
    • “Even if you increase that tenfold, that is still a very tiny risk,” said Dr. Bart Duell, a professor of medicine at Oregon Health and Science University in Portland, who co-authored the AHA report but was not involved in the new research. The risk of muscular side effects “really isn’t a reason to not use statins,” he added.”
  • The Wall Street Journal reports,
    • “Decades of information-based efforts have failed to improve eating habits, requiring bolder action on several fronts.
    • “A new category of “health-span professionals” with graduate degrees would focus on nutrition and healthy longevity.
    • “Time-restricted eating and fasting-mimicking diets are proposed, alongside treating food as medicine via government and insurer support.”
  • MedPage Today adds,
    • “Lower-inflammatory dietary patterns were tied to reduced dementia risk among biomarker-positive older adults.
    • “Benefits appeared strongest for participants with elevated p-tau217, NfL, or GFAP levels.
    • “Findings suggest diet quality may still matter after early Alzheimer’s-related biological changes emerge.”

From the U.S. healthcare business and artificial intelligence front,

  • The Wall Street Journal reports
    • Germany’s Merck MRK KGaA said it struck a deal to buy U.S. life-sciences tools supplier Bio-Techne TECH 0.38%increase; up pointing triangle for $11.3 billion, in an early move under its new chief executive to bulk up its lab-tools business.
    • “The proposed acquisition represents Merck’s biggest deal since its $17 billion buyout of Sigma-Aldrich more than a decade ago and comes weeks after the appointment of Kai Beckmann as CEO.”
  • Health Exec relates,
    • “Irish-American medical device manufacturer Medtronic announced today that it is making a major purchase that will expand its offerings for the treatment of nerve-based chronic pain.
    • “In an announcement, the company confirmed its “intent to acquire” SPR Therapeutics, an Ohio-based developer of non-opioid, non-surgical pain management treatments. The deal—valued at $650 million—would give Medtronic full control of SPR’s offerings, including its core “percutaneous peripheral nerve stimulation” devices, which manage pain unrelated to an acute injury.
    • “Medtronic already has a neuromodulation business, meaning the acquisition will add new options to its portfolio. The group boasted that it has been a leader in neuromodulation—which is most simply defined as the use of nerve stimulation to relieve pain—with the division dating back 50 years.
    • “It said the purchase of SPR will allow it to “reach and support more people” who would benefit from non-pharmaceutical pain relief offerings.”
  • MedTech Dive tells us,
    • “Labcorp has made the colorectal cancer screening test ColoSense available nationwide, boosting access to a challenger to Exact Sciences’ Cologuard.
    • “The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test as a preferred option in its colorectal cancer screening guidelines.
    • “Labcorp secured the right to distribute the test from Geneoscopy in 2023. The Food and Drug Administration approved the test in 2024 and authorized a collection kit in 2025.”
  • Beckers Health IT informs us,
    • “Oakland, Calif.-based Kaiser Permanente has reduced MRI patient wait times by more than 60% using an FDA-cleared AI tool that shortens scan duration without degrading image quality.
    • “The AI solution reduces image noise during MRI scans, trimming average scan time from roughly 45 minutes to about 30, according to a June 24 news release. The shorter sessions allowed Kaiser Permanente to schedule more scans on existing equipment — eliminating the need for costly new machines to meet rising demand.
    • Daniel Yang, MD, the health system’s vice president of AI and emerging technologies, credited governance as being equally important as the technology itself. Kaiser Permanente’s AI councils review proposed deployments before launch, then continue monitoring performance metrics such as scan time, image quality, appointment availability and repeat scan requests.”

Thursday Report

Simplicity is a virtue.

From Washington, DC,

  • STAT News reports,
    • “The chair of the Senate health committee introduced a bill to restrict a federal drug discount program known as 340B that has been lucrative for nonprofit hospitals.
    • “The bill by Sen. Bill Cassidy (R-La.) comes as hospitals face attacks on their bottom lines, especially in Medicaid. The tax bill that Republicans passed last summer significantly decreased the federal government’s share of Medicaid costs and is expected to reduce the number of people on Medicaid. Hospitals also face the prospect of legislation that would lower hospital payments to levels charged by doctor offices, an idea known as site-neutral payments.” * * *
    • “Cassidy’s bill would implement many pharmaceutical-industry backed restrictions on the program. It would allow drugmakers to give hospitals retroactive rebates, instead of the upfront discounts that hospitals prefer. Hospitals could insist on receiving upfront discounts, but only if they pass them on to patients. They’d also need to establish a sliding-fee scale for prescription drugs, effectively sharing some of the discounts with low-income and uninsured patients.” * * *
    • “Similarly, the bill would place restrictions on the contract pharmacies that hospitals use to administer the discounts. Hospitals would be limited to five contract pharmacies, which would be required to be located in a 340B entity’s service area. The bill also would define conditions for contract pharmacies to participate in the 340B program.” * * *
    • “There are also transparency measures in the bill. Hospitals would have to annually report profits from the drug discount program, the number and types of patients who received 340B drugs, and details of charity care they offer.”
  • The Whistleblower Network News relates,
    • “Sen. Chuck Grassley (R-Iowa) is calling on the Office of Personnel Management (OPM) to revise a proposed government-wide nondisclosure agreement, warning that the draft form could discourage federal employees from reporting waste, fraud, and abuse.
    • “On May 27, OPM, the federal government’s chief human resources agency and personnel policy manager, published a notice seeking public comment on a proposed nondisclosure agreement for use by federal agencies with new and existing employees. According to OPM, the proposed form is intended to standardize confidentiality obligations across the federal government and protect non-public, confidential and proprietary information obtained through official duties.
    • “Grassley, who chairs the Senate Judiciary Committee and co-founded the Senate Whistleblower Protection Caucus, warned that the draft does not go far enough to ensure federal employees understand that the agreement cannot override their whistleblower rights. In a letter to OPM Director Scott Kupor, Grassley urged the agency to update the draft NDA to include the full anti-gag provision required by federal law. Grassley also framed the issue as one implicating federal employees’ constitutional rights.”
  • The Wall Street Journal tells us “What to Know About the Government’s $6.5 Billion Healthcare Fraud Crackdown.”
    • “An $865,000 Bulgari necklace, $600,000 spent on vehicles and more are detailed in documents.”
  • The American Hospital Association News tells us,
    • “The House Energy and Commerce Subcommittee on Health June 25 held a markup session on bills regarding healthcare price transparency, illicit drugs and prior authorization. Bills considered by the subcommittee included the Lower Costs, More Transparency Act (H.R. 9393), legislation that would codify existing price transparency regulations for hospitals and health plans; the Prices on the Wall Act (H.R. 9390), a bill that would require hospitals to post pricing physically on their walls; and the Improving Seniors’ Timely Access to Care Act (H.R. 3514), an AHA-supported measure that would reduce variation in prior authorization methods used for Medicare Advantage plans. 
    • “The AHA provided comments to the subcommittee June 10 for a hearing discussing some of the proposals from today’s markup. All of the bills considered June 25 were advanced to the full committee for consideration.”
  • Bloomberg Law informs us,
    • “Out-of-network doctors are winning drastically higher arbitration payouts for planned procedures under a law protecting patients from unexpected emergency bills, according to data from insurer Elevance Health Inc.
    • “Over the last two years, median arbitration awards won by out-of-network doctors for the most common billing codes for planned procedures are 53 times the in-network rate, the insurer said in a paper shared with Bloomberg Law. Elevance said doctors are exploiting a loophole under the No Surprises Act meant to exclude procedures where patients knowingly consent to paying for out-of-network care.” * * *
    • “The No Surprises Act is largely intended to protect patients when they need emergency care at out-of-network hospitals. But it also allows doctors to file arbitration disputes for in-network procedures where the secondary physician, such as an anesthesiologist, is out-of-network. Doctors are prohibited from balance-billing in those situations unless the patient signs a specific waiver acknowledging the additional costs.
    • “Planned procedures made up around 60% of Elevance’s “independent dispute resolution” awards, and the amounts dwarfed those won for emergency care. Overall, arbitration awards for provider groups filing the most disputes are three to nine times higher than in-network benchmarks. Elevance’s data, by contrast, show that doctors performing planned procedures were winning awards 53 times the in-network benchmark rate.”
  • The FEHBlog who represents a payer (not Elevance) in these No Surprises Act cases seconds Elevance’s contention. What’s more an out-of-network primary surgeon can use the No Suprises Act process as long as the surgery occurs in an in-network facility.
  • Per an AHIP news release,
    • “Recent polls show that rising healthcare costs are a top concern for Americans across the political spectrum and voters strongly support common-sense policy solutions to address the root causes driving the healthcare affordability crisis.
    • New polling data from the Century Foundation underscores the breadth of bipartisan support for policy solutions: 
      • “Two-thirds of voters said that the federal government should make “stop[ping] hospitals from charging excessive prices” their top priority – more than any other policy proposal.
      • “Support for reining in hospitals’ ever-higher prices is decisive across partisan and demographic lines, including 71% of Democrats, 66% of Republicans and 75% of rural voters.
      • Six in 10 voters said reining in surprise medical billing by providers should be a top priority – the second-highest priority of all proposals tested.
    • “Voters’ bipartisan concerns are well-grounded in the data. Healthcare costs are rising faster than inflation, driven by unchecked growth in the price of hospital carephysician services and prescription drugs. Americans’ premiums and out-of-pocket costs directly reflect these rising costs.”
  • Tammy Flanagan, writing in Govexec, points out, at the conclusion of a longer article
    • “Even as Medicare and FEHB premiums continue to rise, many retirees still find the combination worthwhile when plans include cost-sharing waivers, rebates or Medicare Advantage structures that shift more costs away from point-of-care spending. Higher-income retirees subject to IRMAA face a sharper calculation: higher fixed premiums today versus potential exposure to higher out-of-pocket costs later. For many, the decision is less about optimization than risk tolerance over time.”

From the Food and Drug Administration front,

  • The New York Times reports,
    • “Doctors treating cancer patients nationwide are facing a shortage of essential generic chemotherapy drugs, a situation that many fear could lead to widespread rationing.
    • “The shortages stem from manufacturing problems, shipping delays and decisions by some companies to stop producing the medications, according to the Food and Drug Administration.
    • “The decades-old medicines are challenging to make in sterile plants and command a very low price in the United States. But they are considered among the most effective treatments for some cancers without more targeted options, including some breast, lung, and head and neck cancers. * * *
    • “From a systemwide policy change, not a single thing has changed,” said Laura Bray, the executive director of Angels for Change, a nonprofit that works to alleviate drug shortages. “It’s time for Washington to get involved and help the citizens of the United States ensure that we have lifesaving medicine.”
  • Fierce Pharma relates,
    • “After 35 years of research and development in pharmaceutical products, Ionis began marketing its drugs for the first time in 2024.
    • “While the company’s maiden voyage into commercialization has progressed “remarkably smoothly,” according to CEO Brett Monia, Ph.D., those efforts will now ratchet up to a new level with the FDA approval of Tryngolza to treat severe hypertriglyceridemia (sHTG).
    • “With the nod, Ionis advances from selling two rare disease drugs to marketing a product that could be used by millions of potential patients.
    • There is no other drug on the market designed specifically to treat sHTG or to combat its accompanying bouts with pancreatitis, which can land patients in the hospital for extended stays and be life-threatening.” * * *
    • “In anticipation of the approval, Ionis’ launch team has been in place since February, promoting Tryngolza to endocrinologists, cardiologists and lipid specialists for FCS while also educating them on sHTG.   
    • “The physicians are just chomping at the bit, waiting to prescribe Tryngolza for their sHTG patients since they manage so many of them,” Monia said.” 

From the judicial front,

  • The Wall Street Journal reports,
    • “The [U.S.] Supreme Court on Thursday ruled for Bayer in its fight against claims that it failed to warn consumers that Roundup causes cancer, boosting the company’s efforts to resolve costly litigation over its popular weedkiller. 
    • “In a 7-2 decision, the court said the pharmaceutical and agriculture company can’t be held liable under state law for failing to warn about the alleged risk when a federal regulator—the Environmental Protection Agency—didn’t require the product to carry a warning label.” * * *
    • “In a statement, a Bayer spokesperson said Thursday’s decision was “good for science, farmers, and industries that depend on regulatory clarity for innovation. It should help significantly contain the Roundup litigation after nearly a decade of legal battles.”
    • “It is a significant victory for Bayer Chief Executive Bill Anderson, who took over the German conglomerate in 2023 with a mandate to help steer it through the litigation. Securing a win at the Supreme Court, along with its proposed settlement, are crucial parts of the company’s strategy to finally move past the long-running Roundup litigation woes.”

From the public health and medical / Rx research front,

  • The Wall Street Journal reports,
    • “Here’s another reason to cover up in the thick of tick season this summer: There is a bite that can leave you allergic to burgers, bacon and steak.
    • “That’s right—Lyme disease isn’t the only health threat ticks can pose. More people are learning about alpha-gal syndrome, a potentially life-changing allergy linked to the lone-star tick.
    • “The condition triggers a red-meat allergy. In some cases, it also causes an allergy to dairy and other products or medication derived from mammals (think gelatin).
    • “And lone-star ticks are on the move, thanks to climate change and burgeoning white-tailed deer populations. They are moving beyond their traditional base in the Southeast and south-central U.S., pushing farther north and west. 
    • “The ticks are especially common in coastal areas, such as Martha’s Vineyard off the coast of Massachusetts and Suffolk County in New York. And no, despite their name, the ticks didn’t originate in Texas. They are called that because of a single white dot on their backs that looks like a single star.” * * *
    • “An added problem: Some doctors believe cases are still being missed. After all, until recently many healthcare providers knew little about the condition caused by lone-star tick bites.
    • A 2023 CDC report found that 42% of healthcare providers had limited knowledge of alpha-gal syndrome and 35% weren’t confident in their ability to diagnose it. 
    • “Patients say misdiagnosis of the syndrome is common and diagnoses can be delayed. That’s because allergic reactions often take place three to six hours after eating the culprit. Among common misdiagnoses: irritable bowel syndrome.”
  • Contemporary Pediatrics tells us,
    • “Researchers found evidence that childhood influences may contribute to 85 adult health diagnoses, including tobacco use disorder, heart disease, digestive disorders, and urinary conditions.
    • “Later age at menarche may serve as a marker of childhood environmental or acquired factors that affect long-term health outcomes.
    • “Findings support the need for greater research into childhood determinants of adult disease and potential prevention strategies across the lifespan.”
  • MedPage Today informs us,
    • “Most in-vitro fertilization (IVF) add-on treatments have little to no evidence of benefit.
    • “Many patients rely on social media and IVF clinic websites for information about them, which may be overhyped.
    • “Better information for patients, and trials of benefits and harms of add-ons are needed.”
    • * * * For example, “[f]our add-ons seemed to have no effect on live birth rates:
      • “EmbryoGlue: OR 1.12, 95% CI 0.91-1.37, P=0.29; seven RCTs; low-certainty evidence
      • “Preimplantation genetic testing for aneuploidy: OR 1.16, 95% CI 0.91-1.47, P=0.23; five trials; moderate certainty
      • “Endometrial receptivity testing: three trials; meta-analysis not undertaken; moderate certainty
      • “Corticosteroids: OR 0.95, 95% CI 0.70-1.27, P=0.71; two trials; moderate certainty.”
  • and
    • “Use and misuse of GLP-1 receptor agonists were common in people with eating disorders, interim results of an ongoing cross-sectional study suggested.
    • “Among over 400 people with eating disorders, 32.1% said they have used GLP-1 drugs, and 22% reported current use, wrote Nicholas C. Peiper, PhD, MPH, of the University of Louisville in Kentucky, and co-authors in a research letter in JAMA Psychiatry.opens in a new tab or window
    • “Notably, 10.1% said they have misused the medications, and 9.9% reported using noncommercial compounded products.”
  • Healio notes,
    • “Omega-3 fatty acids may not deliver benefits for cognitive function on their own, according to a study published in eBioMedicine.
    • “The results show the need for a multimodal approach to preventing dementia in older adults, one that simultaneously addresses physical inactivity, vascular health and other risk factors, Hussein Yassine, MD, director of the USC Center for Personalized Brain Health, and colleagues wrote.”
  • Cardiovascular Business lets us know,
    • “Oral nicorandil can reduce the risk of contrast-associated acute kidney injury (CA-AKI) when patients with renal dysfunction undergo percutaneous coronary intervention (PCI), according to new research published in Circulation: Cardiovascular Interventions.[1] The greatest impact was seen in patients receiving three high doses of the medication per day.
    • “Nicorandil is currently indicated for the treatment of angina. Because it is associated with improved hemodynamics in addition to anti-oxidant and anti-apoptotic benefits, the team behind this study hoped to learn more about its potential effect on high-risk PCI patients who present with renal dysfunction.
    • “Researchers focused on more than 600 patients with renal dysfunction who underwent PCI from 2022 to 2025. While approximately one-third of those patients received 5 mg of nicorandil three times per day, another one-third received 10 mg of nicorandil three times per day. The remaining patients received no nicorandil and served as the study’s control group.
    • “Overall, the rates of CA-AKI within 72 hours were 8.7% for the high-dose group, 10.9% for the conventional dose group and 19.8% for the control group. High-dose nicorandil was linked to a 61% relative risk reduction without significantly increasing the risk of adverse events.”
  • Per BioPharma Dive,
    • “Biotechnology startup RQ Bio has snagged a nine-figure funding round to support development of a drug it believes to be capable of providing broad, long-lasting protection against seasonal influenza.
    • “The London-based biotech said Wednesday it raised 85.5 million pounds, or $115 million, to advance a program known as RQB01. Currently in preclinical testing, the therapy has an undisclosed “differentiated dual mechanism” targeting parts of the virus that remain unchanged even after mutations. RQ Bio claims this approach could help ward off flu-related illness from a variety of different strains, with a single dose providing protective effects that persist for a full season.
    • “The financing round was led by Frazier Life Sciences, included participation from founding investor LifeArc Ventures, and involved other well-known firms such as Forbion and EQT Life Sciences.”

From the U.S. healthcare business front,

  • HealthLeaders reports,
    • “PwC projects a 9.0% commercial medical cost trend for group plans in 2027, driven by structural inflators like AI-enabled documentation tools, rising specialty pharmacy costs, and IDR payments. 
    • “As payers aggressively deploy AI-driven pre-payment reviews to combat rising costs, providers are automating their defenses, creating an expensive administrative arms race that fails to lower systemic costs for the consumer.
    • “To navigate this financial squeeze without alienating their communities, health systems must shift away from back-end collections and prioritize transparent, empathetic pre-service financial clearance.”
  • Beckers Payer Issues relates,
    • “Optum is speaking with multiple large New York health systems to sell some specialties in the state, the company confirmed to Becker’s June 24.
    • “The UnitedHealth Group subsidiary is considering the sale of certain specialties, including orthopedics, general surgery and urology. The specialties are affiliated with Optum Medical Care and Crystal Run Healthcare, which Optum purchased in 2023.
    • “We are in discussions with several large health systems across New York regarding the transition of certain specialty services with the goal to keep that care local,” Jon Nasser, MD, CEO of Optum New York and New Jersey, said in a statement shared with Becker’s
    • ‘Optum has already signed or is negotiating letters of intent with the interested health systems. The company aims to reach agreements and close sales by the end of 2026.”
  • and
    • “Walgreens will begin supporting eligible Medicare beneficiaries through the new Medicare GLP-1 Bridge program at about 8,000 pharmacies when the initiative launches July 1.
    • “More than 56 million patients in the Medicare network may be eligible for the program, according to a June 25 news release. Walgreens pharmacists will help patients navigate eligibility requirements, answer questions about participating medications and provide ongoing support during treatment. Free delivery will be available in most states for select oral GLP-1 tablets, as well.
    • “Walgreens joins CVS Health, Walmart and Sam’s Club in supporting the Medicare GLP-1 Bridge program. CVS said it will offer expanded pharmacist support, a $49 MinuteClinic virtual weight management visit and a $50 monthly copay option for eligible Medicare beneficiaries. Walmart and Sam’s Club said they will provide pharmacist consultations and educational resources through nearly 5,000 pharmacy locations.”
  • Beckers Hospital Review tells us,
    • “Orlando Health Watson Clinic Lakeland (Fla.) Highlands Hospital is scheduled to open July 8 after more than six years of construction and planning.
    • “The more than $500 million facility is the first hospital opening in Lakeland in over a century, and Orlando Health’s 50th facility in Florida, including clinics, freestanding emergency departments, hospitals, and institutes, according to a June 25 news release shared with Becker’s
    • “Orlando Health Watson Clinic Lakeland Highlands Hospital has hired 1,500 employees, and is offering full scholarship programs to full- and part-time staff. The 558,233-square-foot facility has seven floors, 206 patient beds, 49 emergency room beds and sits on nearly 80 acres.
    • “The hospital has eight labor and delivery beds, 28 postpartum rooms and two cesarean section operating rooms. In the next few months, it will open a neonatal intensive care unit that comprises 12 beds for babies who need specialized postbirth care.”
  • Radiology Business adds,
    • “The University of Pittsburgh Medical Center recently held a ribbon cutting for an $8 million new interventional radiology suite. 
    • “UPMC Williamsport, a 224-bed acute care hospital, said the relocated IR facility seeks to bring minimally invasive care closer to home for patients in north central Pennsylvania. The upgraded suite now includes two state-of-the-art labs, equipped with next-generation imaging systems. 
    • “UPMC said the scanners will allow radiologists to visualize blood vessels and internal structures in real time. There, they’ll deliver procedures including stent placements and balloon angioplasties with “greater accuracy and control.” 
    • “This investment reflects UPMC’s ongoing commitment to expanding access to advanced, high-quality care across north central Pennsylvania,” Luke Klingler, director of the health system’s Heart and Vascular Institute, said in an announcement June 17. “The new interventional radiology suite strengthens our ability to meet the evolving needs of our communities by enhancing clinical capabilities, supporting multidisciplinary collaboration, and ensuring patients can receive leading-edge, minimally invasive care close to home.”
  • MedCity News informs us,
    • “Michigan-based insurer Priority Health has teamed up with Garner Health, a digital platform that steers patients to high-performing doctors to lower costs, the companies announced on Wednesday.
    • “Priority Health serves 1.4 million members in Michigan, Indiana, Ohio and Wisconsin. The new partnership will support both self-funded and fully funded employer groups, and will become available starting August 1.
    • ‘The partnership seeks to make it easier for Priority Health’s members to find high-quality physicians in their area. Garner Health has a dataset of over 60 billion medical records that helps identify the best quality doctors. When members choose high-performing providers through Garner’s dataset, their employer then covers most or all of their out-of-pocket costs. This incentivizes employees to choose better doctors and lowers costs for employers by avoiding unnecessary procedures.”
  • Per Fierce Healthcare,
    • “Virtual care platform First Stop Health unveiled an expansion of its Healthy Weight Program amid increasing GLP-1 demand and subsequent healthcare plan costs.
    • “The program integrates weight management, including GLP-1 prescriptions when appropriate, directly into its primary care model. New to the program is a cash-pay access option for employers who do not currently cover GLP-1 prescriptions and a managed coverage program for those who do offer coverage. 
    • “The goal isn’t simply weight loss — it’s improving metabolic health and reducing long-term health risk,” said Cole Barfield, M.D., First Stop Health chief medical officer, in an emailed statement to Fierce Healthcare. 
    • “Barfield said the virtual care platform aids “employers on either side of the coverage decision” by “combining clinically appropriate prescribing with primary care, dietitians, health coaches, and diabetes educators who support sustainable behavior change.” 
    • “Medication can be transformative, but it works best when it’s part of a real care relationship focused on the whole person,” Barfield said.”